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ABSTRACT 
 
Development of bioinformatic tools to identify and characterize linear protein epitopes 
by 
Michael Louis Paull 
 
 The adaptive immune system produces antibodies to specifically target antigens. 
Identifying and characterizing epitopes on target antigens enables numerous medical 
applications such as vaccine design, diagnostic discovery, and therapeutic antibody 
development. We have developed computational tools that characterize epitopes using large 
sets of antibody-binding peptides. To identify epitopes in target proteins, we used an 
approach termed K-mer Tiling of Protein Epitopes (K-TOPE). In this approach, we divided 
protein sequences into short overlapping subsequences of length k (k-mers). Then, we 
defined and scored epitopes using each k-mer’s enrichment in the sets of antibody-binding 
peptides. Using K-TOPE, we accurately identified epitopes for monoclonal and polyclonal 
antibodies. Next, using 250 specimens, we identified commonly targeted epitopes in nearly 
3,000 viral proteins as well as two bacterial proteomes. Importantly, these epitopes agreed 
with previously reported results. To map antibody binding in epitopes, we developed 
Multiplexed Epitope Substitution Analysis (MESA). In this approach, target epitopes were 
divided into short overlapping k-mers. Then, each k-mer was exhaustively substituted with 
all amino acids. The effects of these substitutions were used to identify amino acid 
preferences at important binding positions in the epitopes. By applying this method to 
monoclonal antibodies and multiple sets of specimens, we identified binding motifs which 
agreed with an alternative computational approach. Finally, K-TOPE and MESA were used 
ix 
 
to characterize epitopes and antigens in age-related macular degeneration (AMD), herpes 
simplex virus (HSV), and Chagas disease. We identified 42 AMD-specific epitopes, 30 
HSV2-specific epitopes, and 222 Chagas-specific epitopes. Several epitopes were in 
validated antigens while many were novel. MESA demonstrated that generally only 4-5 
positions in these epitopes were important for binding. Future application of these 
approaches could enhance our understanding of the role that antibodies play in disease 
progression. 
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1 Introduction 
 
1.1 Motivation 
 
 Antibodies are produced by the adaptive immune system to target pathogens. Since 
antibodies specifically bind to a single target, they have found numerous uses in biological 
sciences and engineering. Additionally, since antibodies are a key arm of the immune 
response, there is interest in understanding their role in the progression of disease. There are 
numerous cases in which serum antibodies either indicate disease, exacerbate illness, or 
protect against infection. For instance, the presence of antibodies towards viruses, bacteria, or 
parasites can be indicative of an infection. In the case of autoimmune diseases, an 
autoantibody targeting self-tissues could be related to the exacerbation of a disease. Finally, 
vaccines generate protective antibodies and are therefore routinely administered to prevent 
infections. In all these cases, the ability to determine the presence of antibodies in a subject’s 
serum is vital. 
 For many applications, it is important to know the target of an antibody (the antigen) 
and where it binds on its target (the epitope). Therefore, rather than focusing on the 
antibodies themselves, it is often sufficient to focus on antigens. Some methods analyze the 
structure of antigens to determine epitopes [1]. However, without experimental antibody 
binding data, the antigens targeted by a specific individual cannot be determined. 
Experimental methods to determine epitopes generally select antibody-binding peptides from 
peptide libraries [2]. Large random peptide libraries can effectively mimic epitopes and 
therefore bind numerous antibodies. By starting with a random library, epitopes for any 
protein antigen can be identified regardless of whether the antigens are from bacteria, 
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viruses, parasites, fungi, or animals. Screening these libraries with serum results in large sets 
of antibody-binding peptides which encode epitope information. Parsing these rich datasets 
to identify epitopes and their corresponding antigens can be challenging. An algorithm which 
could consistently meet this challenge would enable the determination of an “immune 
history” from an individual’s serum. This immunological record would contain epitopes and 
antigens corresponding to active and past antibody responses. With the immune histories of 
many individuals, epitopes and antigens could be identified to enhance our ability to 
understand, diagnose, and treat various diseases.  
1.2 Dissertation organization  
 
This dissertation describes the development and application of algorithms that 
identify and characterize linear antibody epitopes. While there are research groups that 
routinely generate antibody-binding peptide datasets, there is a lack of computational 
schemes that can comprehensively identify linear epitopes and connect them to antigens. For 
our approach, we identified antibody-binding peptides using a random peptide library and 
processed these peptide sequences into short k-mers. These k-mers were then manipulated to 
characterize linear epitopes for a variety of protein antigens. To validate these methods, 
epitopes were generated for common pathogens as well as three diseases with antibody-
related pathology. 
 Chapter 1 of this dissertation discusses recent studies that mapped antibody 
repertoires using peptide libraries, describes three model disease systems, and explains 
relevant experimental techniques. Chapter 2 describes the development and initial validation 
of the K-mer Tiling of Protein Epitopes (K-TOPE) algorithm. This algorithm uses k-mers 
from antibody-binding peptides and candidate antigen sequences to determine linear 
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epitopes. In Chapter 3, Multiplexed Epitope Substitution Analysis (MESA) is introduced, 
which uses k-mers to map antibody binding in epitopes. This method reveals the positions in 
an epitope that are important to binding and the amino acid preferences at those positions. In 
Chapter 4, these two algorithms are applied to age-related macular degeneration, herpes 
simplex virus, and Chagas disease. These analyses revealed several novel disease-specific 
antigens and epitopes. Finally, we summarize these studies and present future opportunities 
for applying K-TOPE and MESA in Chapter 5.  
1.3 Mapping serum antibody repertoires using peptide libraries 
 
Antibodies in blood provide a rich source of immunological information. Antibody 
repertoire analysis seeks to decode this information to empower the development of vaccines, 
diagnostics, and therapeutics. To this end, various approaches have been developed to 
determine epitopes using peptide libraries. Approaches have used random or proteome-
derived peptide libraries in a microarray or surface display format. For methods using 
random libraries, motif discovery software has been developed to identify common binding 
signatures. The analysis of thousands of samples and dozens of diseases has shown that there 
are often disease-specific epitopes, even though individual antibody repertoires are unique. 
The recent developments in antibody repertoire analysis hold the potential to enable 
comprehensive immune evaluations. 
1.3.1 Background 
Antibodies bind specifically to their targets and are therefore relevant to numerous 
scientific, medical, and industrial applications. The immune system continuously makes 
antibodies even after an infection has been resolved. Therefore, the antibodies in serum 
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constitute an immunological record. The ability to access and interpret this record could 
impact many areas of biotechnology and healthcare. In particular, the identification of 
disease-associated antigens has enabled the development of numerous diagnostic tests for 
infectious [3], autoimmune [4], and allergic conditions [5]. Furthermore, epitope information 
can be used to inform the development of more efficacious vaccines [6]. With the growing 
number of antibody-based therapeutics, there is a need to characterize antibody binding to 
measure specificity and avoid undesired cross-reactivity [7]. Additionally, knowledge of 
antibody binding sites can enable the design of more effective affinity reagents for diverse 
applications [8]. Finally, antibody repertoire analysis methods will augment efforts to 
characterize the “healthy” antibody repertoire which could be useful for detecting the onset 
of disease [9]. With the recent development of high-density peptide microarrays, high-
throughput sequencing, and increased computational power, there is increasing interest in 
antibody repertoire analysis. 
Although the expression “antibody repertoire” is frequently used, it is informative to 
divide its usage into methods focusing on paratopes or epitopes. The terms paratope and 
epitope refer to the binding regions of the antibody and antigen, respectively (Figure 1.1). 
Paratope-focused methods analyze antibody CDR regions through B-cell DNA sequencing 
and LC-MS/MS [10,11]. These methods have proven useful for monitoring the evolution of 
an immune response, determining which antibody clonotypes are most abundant, and 
investigating class switching [12]. Alternatively, methods that identify protein epitopes have 
the distinct advantages of requiring minimal serum, rather than B cells, and allowing for the 
identification and analysis of antigens. This review focuses on approaches that use peptide 
libraries to determine protein epitopes for the antibody repertoire. 
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Figure 1.1: An overview of the classification of antibody/antigen binding interactions. 
The paratope and epitope refer to the binding regions of the antibody and antigen, 
respectively. Paratope-focused methods focus on serum antibodies or antibody-producing 
B-cells. Epitopes can be comprised of non-protein molecules such as glycans, lipids, 
nucleic acids, combination structures, or synthetic molecules. Continuous protein epitopes 
are comprised of a single sequence whereas discontinuous protein epitopes are comprised 
of amino acids distant in sequence, but close in the folded protein. 
 
1.3.2 Protein epitope characteristics 
Protein epitopes are typically considered to be continuous (“linear”) or discontinuous 
(“conformational”) (Figure 1.1). Continuous epitopes are comprised of a single sequence 
whereas discontinuous epitopes are comprised of amino acids distant in sequence, but close 
in the folded protein. For the cases in which the epitopes of interest are discontinuous, 
several methods have been developed [1,13,14]. It has been suggested that because >90% of 
epitopes are discontinuous, searching for continuous epitopes may be fruitless [15]. 
However, from an analysis of PDB antibody/antigen structures, it was determined that 
epitopes are generally composed of around 15 residues and that 85% of epitopes contain at 
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least one 5 amino acid contiguous stretch [16,17]. Strictly speaking, nearly all epitopes are 
discontinuous, however, the frequent occurrence of linear segments suggests that there is 
utility in identifying linear epitopes [18]. And importantly, linear protein epitope discovery 
remains bioinformatically tractable. 
Figure 1.2: A general flow diagram for mapping antibody repertoires. First, peptide 
libraries are designed using random or non-random libraries displayed in a microarray or 
surface display format. Next, the peptide library is combined with serum and antibody-
binding peptides are selected. Finally, bioinformatics is used to identify epitopes and 
associate epitopes with antigens using sets of antibody-binding peptides. 
1.3.3 Classification of antibody repertoire mapping approaches 
Approaches for mapping the antibody repertoire use random or non-random peptide 
libraries in a microarray or surface display format (Figure 1.2) [19]. For microarrays, 
peptides are typically printed or synthesized on glass slides, whereas for surface display, 
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peptides are most often displayed on bacteriophages, bacteria, or yeast. Relevant information 
for each approach referenced in this review can be found in Table 1.1. 
Non-random methods often use libraries constructed by tiling target protein 
sequences into overlapping peptides. While the concept of determining epitopes by tiling 
antigens seems straightforward, there are important limitations. There is reason to believe 
that, paradoxically, random peptides may be able to capture binding specificities that the tiled 
antigens themselves cannot [20]. One potential explanation for this observation could be that 
an antibody binds to a peptide from a random library with higher affinity than the 
corresponding fragment of the antigen. Further, proteome-derived peptide libraries are 
typically several orders of magnitude smaller than random libraries (e.g. 105 [21] vs. 1011 
[22]). 
The use of random libraries allows for a less biased experimental approach to epitope 
determination. However, with random libraries, the burden shifts to computational motif 
discovery since it is necessary to resolve randomness into a coherent signal. Additionally, 
associating an epitope with an antigen becomes a challenge. 
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Table 1.1: Information about recent antibody repertoire analysis studies. The sample 
size, sample classification (disease/condition studied), library size, and year of publication 
are listed for the studies discussed. For studies using multiple libraries, the library size refers 
to the largest library. The sample size corresponds to the experiments using the largest library 
and includes both experimental and control groups. For studies with humans and animals, 
human sample sizes were used. In some cases, parameters were ambiguous and had to be 
inferred from the manuscripts. 
 
Category Sample size Sample Classifications Library Size Year Reference 
Non-Random 
Microarrays 
30 Multiple sclerosis 4E+03 2016 [23] 
 
19 Chagas disease 2E+05 2015 [24] 
 
10 Multiple sclerosis, 
narcolepsy 
2E+06 2017 [25] 
 
22 Polyclonal antibodies 2E+06 2012 [26] 
 
5 Polyclonal antibodies 2E+06 2014 [8] 
Non-Random 
Surface Display 
3 Paraneoplastic syndromes 4E+05 2011 [27] 
 
569 Multiple viral infections 9E+04 2015 [28] 
 
61 Dengue virus 4E+03 2017 [29] 
 
298 Multiple sclerosis, 
type 1 diabetes, 
rheumatoid arthritis 
4E+05 2013 [21] 
Random 
Microarrays 
11 Alzheimer’s disease 1E+04 2012 [30] 
 
61 Pancreatic diseases 1E+04 2012 [31] 
 
125 Multiple viral infections, 
multiple cancers 
3E+05 2014 [32] 
 42 Myalgic encephalomyelitis 1E+05 2016 [33] 
 
1516 Multiple viral infections, 
multiple cancers 
1E+04 2014 [34] 
 
106 Multiple viral and bacterial 
infections, 
malaria 
3E+05 2015 [35] 
 
73 Healthy controls 3E+05 2016 [9] 
Random Surface 
Display 
1 Human immunodeficiency 
virus 
2E+09 2012 [36] 
 
5 High-grade epithelial 
ovarian cancer 
1E+11 2016 [22] 
 
14 Human immunodeficiency 
virus 
1E+09 2013 [37] 
 
10 Vaccinations 1E+09 2013 [38] 
 
2 Healthy controls 1E+09 2017 [39] 
 
12 Peanut allergies 1E+09 2015 [40] 
 
88 Celiac disease 1E+10 2012 [41] 
 
38 Pre-eclampsia 8E+09 2016 [42] 
 
29 Celiac disease 8E+09 2016 [43] 
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Microarrays are potentially more reproducible, less laborious, and more quantitative 
than surface display systems. However, microarrays usually display 3-5 orders of magnitude 
fewer peptides than surface display libraries, which can attain library diversities up to 1011. A 
consequence is that microarrays may not contain enough information for certain applications. 
Also, surface display peptide libraries can be propagated by growth which reduces cost. 
1.3.4 Non-random microarray methods 
For non-random microarrays, antigens from a pathogen of interest or the human 
proteome are tiled into overlapping peptides. Multiple Sclerosis (MS) autoantibodies have 
been examined in depth using a microarray with presumed MS autoantigens and Epstein-Barr 
Virus (EBV) antigens [23]. This analysis discovered peptides that were bound by the serum 
antibodies of MS subjects, but not by matched controls. A peptide containing “RRPFF” from 
EBV Nuclear Antigen 1 (EBNA1) was stated to be disease-specific, however a study with a 
larger sample size showed that this epitope was prevalent in the general population [21]. 
Antigens of the parasitic protozoan Trypanosoma cruzi have been tiled to analyze serum 
samples from subjects infected with Chagas disease [24]. In this case, the use of high-density 
microarrays identified multiple new disease-specific peptides and antigens. However, only a 
fraction of Trypanosoma cruzi antigens could be examined because of the large size of this 
parasite’s proteome. These examples demonstrate that microarray size can restrict the 
number of serum samples and antigens that can be analyzed. 
Another method used a human proteome microarray with six amino acid lateral shifts 
followed by a targeted microarray with only single amino acid shifts [25]. This method 
identified two potential novel autoantigens for narcolepsy and multiple sclerosis. An 
approach for determining the fine specificity of epitopes used a non-random microarray, 
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followed by an exhaustive mutagenesis scheme on selected epitopes [26]. The scheme was 
later refined and made available through the online server ArrayPitope [44]. 
1.3.5 Non-random surface display methods 
An exemplar surface displayed non-random library is T7-Pep, in which peptides 
representing the human proteome are incorporated into a phage library [27]. Human 
proteome libraries are useful for probing autoantibodies using phage immunoprecipitation 
sequencing (PhIP-Seq). The initial application of this method identified candidate 
autoantigens in subjects with paraneoplastic syndromes. T7-Pep was also used for a large-
scale PhIP-Seq screen of nearly 300 antibody repertoires from subjects with type 1 diabetes, 
multiple sclerosis, rheumatoid arthritis, and healthy controls [21]. Most antibody-binding 
peptides were unique to individuals, suggesting that each antibody repertoire is unique. Even 
with large sample sizes, disease-specific peptides with high sensitivity were not found. Their 
absence may be due to disease heterogeneity or the inherent stochasticity of the humoral 
response. 
One of the largest antibody repertoire studies to date screened 569 antibody 
repertoires using a phage library with peptides tiling virtually all human-host viruses [28]. By 
including known infected serum specimens, researchers could identify virus-specific 
epitopes. This study found that there were “public epitopes” bound by the antibodies of many 
subjects. There were also notable differences in the epitopes bound by subjects of varying 
ages and geographic locations. One limitation of this method was that it used 56 residue 
peptides which makes it difficult to localize an epitope to its core 5-10 amino acids. Also, 
vaccine-related epitopes for common viruses such as measles and rubella were not observed 
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in this study [45]. A smaller scale study used a library derived from the Dengue virus 
proteome and found shared epitopes in infected subjects [29]. 
1.3.6 Random microarray methods 
Immunosignaturing uses 104-105 random peptides displayed in a microarray format to 
profile the antibody repertoire [46–48]. Immunosignaturing has been used to profile the 
antibody repertoires of transgenic mice with an Alzheimer’s disease (AD) phenotype to 
identify distinct signatures at different time points in disease progression [30]. Interestingly, 
these results suggested that humans with AD had detectable immunological similarity despite 
having distinct personal antibody repertoires. In other studies, immunosignatures 
differentiated between similar pancreatic diseases [31], between multiple cancers and 
infectious diseases [32], and between myalgic encephalomyelitis disease subjects and 
controls [33]. Microarrays were also used to successfully classify more than 1500 serum 
specimens into 15 disease groups [34]. Since many diseases and specimens were 
simultaneously and successfully classified, this lends support to the idea that a single peptide 
microarray could potentially identify many distinct diseases. 
Subsequences have been used instead of sequences in BLAST searches to identify 
potential associations between epitopes and pathogen antigens [35]. Researchers determined 
that in a BLAST search of pathogen proteins, the true antigen can be resolved if a pair of 
pentamers exactly match the antigen or a pair of heptamers have 80% identity. However, this 
strategy makes the restrictive assumption that an antigen of interest has multiple significant 
epitopes. To address the changes in the antibody repertoire in “healthy” humans, 
immunosignaturing was used on longitudinal serum samples and determined that a person’s 
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immunosignature remains fairly constant over time [9]. Despite this consistency, signatures 
corresponding to vaccinations administered during the study were observed. 
1.3.7 Random surface display methods 
A method that exemplifies random surface display is Deep Panning, which uses a 
large random phage library and Next-Generation Sequencing (NGS) [36]. In this case, the 
clustering algorithm MEME was used to identify motifs within the set of selected peptides 
[49]. Phage display and NGS have also been used to identify tumor-associated antigen 
peptides for high-grade epithelial ovarian cancer [22]. To identify epitopes associated with 
HIV, rhesus macaques were vaccinated against HIV and vaccination-specific epitopes were 
found using biopanning [37]. 
 Studies have shown that motifs typically require seven fixed amino acids to identify 
specific antigens within the entire non-redundant database using BLAST [50,51]. Although, 
if database searches were restricted to specific proteomes or if multiple motifs could be 
matched to a protein, it was possible to reach statistical significance [38]. A combination 
approach was employed which identifies antibody-binding peptides using a random phage-
displayed library, assays these peptides in a microarray format, and uses an additional 
microarray for substitution analysis [39]. Peptides were clustered using the MEME algorithm 
and the resultant motifs were analyzed using BLAST to identify candidate antigens within 
common pathogens. 
Phage display and NGS were used to investigate IgE epitopes from subjects with 
peanut allergies [40]. Selected peptides were aligned to a known peanut allergen and pairwise 
clustering was used to determine motifs. Interestingly, this study demonstrated that subject-
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specific motifs could be observed in early selection rounds. This observation suggests that 
motifs could be identified with fewer selection rounds, which could help avoid selection bias. 
Peptide libraries displayed on bacteria have also found utility in antibody repertoire 
analysis [52,53]. Bacterial display libraries of random peptides have been used to identify a 
panel of diagnostic peptides for celiac disease [41]. Similarly, bacterial display was used to 
identify disease-associated epitopes in subjects with pre-eclampsia [42]. Molecular mimicry 
was suspected since a prominent consensus motif was linked to EBNA1, which in turn 
exhibited similarity to a human protein, GPR50. This demonstrates that antibody repertoire 
analysis could also focus on the environmental causes of autoimmune diseases brought on by 
molecular mimicry. 
1.3.8 Motif identification algorithms 
A significant limitation of the commonly employed motif discovery algorithm, 
MEME, is that it scales approximately quadratically with the number of input sequences. It is 
therefore necessary to reduce a list of antibody-binding peptides to less than about 5000 
sequences. This is often accomplished through additional selection rounds which can 
detrimentally remove relevant peptides. In an effort to address the limited throughput of 
MEME, the MUSI algorithm was developed which can quickly identify multiple motifs in 
tens of thousands of sequences [54]. This method represents a time complexity improvement 
over MEME, though it is not clear how well it would scale to datasets of greater than 105 
sequences, which are routinely generated using NGS. Gibbs clustering has also been used to 
discover motifs in large datasets [55]. This algorithm has greater accuracy than MUSI, but 
may be slower. 
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The anchor based sequence clustering algorithm (ASC) focuses on a preliminary 
clustering step, followed by using existing algorithms to identify motifs within the clusters 
[56]. This algorithm outperformed previous motif discovery algorithms such as MEME, 
MUSI, and Gibbs clustering. Another algorithm that discovers motifs in large datasets is 
IMUNE, in which antibody-binding peptides are reduced to a set of enriched patterns which 
are then clustered together to determine motifs [43]. Using IMUNE, disease-specific motifs 
for celiac disease were identified. Since IMUNE reduces large sets of peptides to patterns, 
the algorithm’s runtime is approximately linear with respect to the initial number of peptides. 
1.3.9 Summary 
Antibody repertoire analysis methods hold the potential to substantially increase our 
understanding of adaptive immune responses. Various approaches have been developed that 
will likely fill different niches. Microarray-based methods offer potential benefits in terms of 
ease of use and assay time. However, approaches using surface display may be better for 
epitope and antigen discovery since they offer significantly larger libraries. Tiled libraries 
could be useful for testing specific hypotheses about suspected antigens. Although, for the 
exploration of a large variety of antibody-antigen interactions, random libraries offer more 
flexibility. 
To analyze large datasets, it is generally useful to reduce the peptide sequences to 
subsequences or motifs. This transformation is performed by Richer et. al. [35], MUSI [54], 
Gibbs Clustering [55], anchor based sequence clustering [56], and IMUNE [43]. Mapping 
epitopes to their corresponding antigens when using random libraries remains a significant 
challenge. Motifs discovered in peptide datasets are often too short to definitively connect to 
antigens using a protein database search. 
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Antibody repertoire analysis will continue to fuel the discovery of disease-specific 
epitopes and the development of diagnostic assays. In addition, these approaches could 
inform the development of therapeutics for cancer, infections, and autoimmune diseases. 
Antibody repertoire analysis may also aid efforts to develop vaccines and quantitatively 
measure their efficacy. We are approaching a point at which we will have the capability to 
consistently access this hidden cache of immunological information. 
1.4 Diseases with antibody-related pathology 
Three diseases with prominent antibody responses are age-related macular 
degeneration (AMD), herpes simplex virus (HSV), and Chagas disease. Analyzing these 
antibody responses could aid the discovery of epitopes that indicate disease. Also, identifying 
the targets of antibody responses could reveal disease etiologies, which would aid therapeutic 
and vaccine development. 
1.4.1  Age-related macular degeneration (AMD) 
Age-related macular degeneration (AMD) is the leading cause of blindness in the 
developed world [57]. Ageing is the key risk factor for AMD, since the immune system 
becomes increasingly dysregulated with age [58]. This dysregulation leads to an increased 
susceptibility to autoimmune diseases and the generation of self-reactive autoantibodies. 
AMD causes a progressive loss of central vision due to atrophy of the retinal cells, which is 
known as the “dry” or atrophic form, or abnormal blood vessel growth, which is referred to 
as the “wet” or neovascular form [59]. Around 90% of AMD cases are the less severe dry 
form, but these cases can lead to the accelerated vision loss of the wet form [60]. There are 
currently 10 million people with vision impairment as a result of AMD, with 2 million people 
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that are blind [61]. Globally, the prevalence of AMD for ages 45-49 years is 4.2%, but jumps 
to 27.1% for ages 80-84 years [62]. 
In AMD, death of the retinal pigment epithelial (RPE) cells and photoreceptors 
occurs in the macula, which is a small area in the back of the eye that is responsible for the 
majority of useful vision [63]. The RPE cells are responsible for nourishing photoreceptors as 
well as transporting away their metabolic waste [64]. Disruption of these duties is related to 
the accumulation of extracellular deposits called drusen between the RPE cells and an 
adjacent basement membrane complex called Bruch’s membrane [65]. The correlation 
between the presence of drusen and the early stages of AMD is sufficiently strong that the 
presence of drusen is used as one of the main diagnostic criteria for AMD [66]. There is no 
cure for AMD and effective treatment exists only for the wet form and consists of 
photodynamic therapy and anti-vascular endothelial growth factor drugs [67]. 
A mounting body of evidence suggests that the immune system plays an integral role 
in the progression of AMD [63,68–70]. This role has been demonstrated by the presence of 
complement proteins in drusen, the presence of anti-retinal antibodies, and the increased risk 
of AMD in patients with an elevated number of memory T-cells [71]. A key finding for 
AMD was that a single nucleotide polymorphism in the immune regulatory protein 
Complement Factor H (CFH) led to a 2.5- to 6.0-fold increase in AMD risk [72]. This 
finding was used to develop a monoclonal antibody drug that targets Complement Factor D, 
lampalizumab, for the treatment of dry AMD [73]. Notably, autoantibodies against human 
proteins have been found in the sera of AMD patients [74–81]. Efforts to elucidate the 
autoantibody targets that contribute to the pathology of AMD have focused on LC-MS/MS 
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[78,81] and protein microarrays [80]. There would be clear utility in identifying reliable 
serological biomarkers for the diagnosis of AMD [59,82].  
1.4.2 Herpes simplex virus (HSV) 
Herpes simplex virus 1 (HSV1) and herpes simplex virus 2 (HSV2) cause human 
infections in the orofacial region (“cold sores”) and the genital region (genital ulcers), 
respectively [83]. HSV is characterized by its ability to reactivate in the present of humoral 
immunity after a period of latency [84]. This latency along with an elaborate system for 
blocking host immune responses increases the pathogenicity of HSV. In addition to mild 
recurrent labial or genital lesions, HSV can cause keratoconjunctivitis, visceral HSV 
infections in immunocompromised hosts, HSV encephalitis, and lethal neonatal infections 
[84]. In 2012, the global prevalence of HSV1 was 3.7 billion people ages 0-49 [85] and the 
global prevalence of HSV2 was 417 million people ages 15-49 [86]. HSV2 has synergy with 
HIV, increasing the risk of HIV-acquisition by three-fold, increasing transmissibility by five-
fold, and accelerating HIV disease progression [86]. Thus, current research efforts are 
generally focused on developing HSV2-specific diagnostics. 
HSV1 and HSV2 contain the same genes [87] and the protein-coding regions of the 
HSV1 and HSV2 genomes share 83% sequence homology [88]. The only striking instance of 
a protein that varies significantly between the two viruses is glycoprotein G [89]. Since 
glycoprotein G is the optimal candidate for identifying HSV2-specific diagnostics, it has 
been a frequent target in epitope mapping [90–92]. As a result of these analyses, glycoprotein 
G and its epitopes have been used in diagnostics for HSV2 [93,94]. Several envelope 
glycoproteins have been characterized as potential diagnostics since they are accessible to 
antibodies on the exterior of the virus [95–100]. Recently, both HSV1- and HSV2-specific 
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epitopes have been identified by using a microarray to analyze the glycoproteins [101]. Thus, 
identifying epitopes for the glycoproteins or even the whole proteomes of HSV1 and HSV2 
could aid in the development of effective diagnostics. 
1.4.3 Chagas disease 
Chagas disease is a chronic infection by the parasitic protozoan Trypanosoma cruzi 
(T. cruzi) that can lead to cardiomyopathy and digestive megasyndromes [102]. The 
protozoan is primarily transmitted to humans by large, blood-sucking insects called 
triatomines (“kissing bugs”) [103]. In addition to parasite-specific responses, heart-specific 
autoimmune responses have been identified for Chagas disease [104]. This disease affects 8 
million people in Latin America [102], with an estimated incidence of 4% per year in 
endemic regions [105]. Chagas disease is the most important parasitic disease in the western 
hemisphere with a disease burden of 7.5 times that of malaria [105]. This burden makes 
Chagas disease the leading cause of cardiac lesions in young, economically productive adults 
in Latin America [106]. While the acute phase of Chagas disease resolves spontaneously in 
90% of individuals, 30-40% of patients develop a chronic form with cardiac and digestive 
pathology 10-30 years after the initial infection [102]. Thus, it is important to have an 
effective diagnostic for Chagas disease to treat patients before serious symptoms develop 
[107,108]. 
 The genome of T. cruzi has been fully sequenced [109], enabling the analysis of 
multiple T. cruzi antigens. Epitopes have been identified for trypomastigote small surface 
antigen (TSSA) [24,110,111], which plays an important role in infectivity [112]. This antigen 
has already found utility as a Chagas diagnostic [113]. Additional studies have identified 
Chagas-specific epitopes using a proteome-derived microarray [24], a random microarray 
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[114], and a random surface-displayed library [115]. Multiple T. cruzi antigens have been 
identified including mucin TcMUCII [114,116], trans-sialidase [117], dispersed gene family 
protein 1 (DGF-1) [114,118], surface antigen 2 (B13) [119], and mucin-associated surface 
protein (MASP) [120–122]. Importantly, since the causative agent for leishmaniasis, 
Leishmania major (L. major), has 85% cross-reactivity with T. cruzi [119], diagnostics need 
to differentiate between Chagas disease and leishmaniasis [123]. By including epitopes from 
known T. cruzi antigens in an ELISA, researchers diagnosed Chagas disease with high 
sensitivity and specificity against leishmaniasis [116]. Taken together, these studies suggest 
that it would be impactful to identify novel Chagas-specific epitopes. 
1.5 Techniques 
 
1.5.1 Magnetic selection 
An in-depth protocol for the experimental techniques used in this dissertation can be 
found in a recent study [124]. Briefly, a large, random 12-mer peptide library with 
approximately 8 X 109 members was displayed as part of the transmembrane protein eCPX 
on E. coli. The main goal of these experiments was to isolate cells displaying antibody-
binding peptides. This was accomplished by combining human serum with the peptide 
library and sorting for antibody-binding library members. 
 One possible concern with this approach is that antibodies could bind to the E. coli 
cell surface directly, rather than to the displayed peptides. To avoid this scenario, serum was 
depleted of E. coli binding antibodies. The serum depletion was performed by first 
combining serum and cells displaying only the protein eCPX. All antibodies that bound cells 
directly were removed, leaving the depleted serum.  
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Once serum was depleted, the bacterial library was sorted using magnetic selection 
(Figure 1.3A). To magnetically label cells that display antibody-binding peptides, we used 
protein A/G magnetic beads. These beads bound to the constant region of the antibodies, 
whereas the peptides bound to the variable region of the antibodies. To prepare a “cleared 
library” of cells that do not bind directly to the beads, peptide-displaying cells were 
combined with beads. Then, a magnet was applied to remove cells that bound directly to the 
beads. Next, we combined the depleted serum with the cleared library, added magnetic 
beads, and applied a magnet to sort for cells displaying antibody-binding peptides. These 
sorted cells were denoted “the enriched population”. Finally, the entire magnetic selection 
procedure was repeated, except starting with the enriched population rather than the initial 
library. 
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Figure 1.3: Magnetic selection and flow cytometry validation. (A) We combined 
peptide displaying bacteria with serum and then washed away unbound antibodies. Next, 
we added magnetic beads which bound to the constant region of antibodies. We applied a 
magnet to capture cells with bound antibodies and then washed away unbound cells. The 
plasmids from this enriched population of bacteria were collected and sequenced. (B) We 
combined the enriched population of bacteria with serum and a fluorescent secondary 
antibody. The cells were examined with a laser such that cells with a higher quantity of 
bound antibodies had higher intensity fluorescence. This measurement revealed the 
percentage of cells in the enriched population that bound antibody. 
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1.5.2 Flow cytometry validation 
We utilized flow cytometry to confirm that a majority of the enriched population 
could bind antibodies (Figure 1.3B). In flow cytometry, a laser is directed at cells suspended 
in small droplets to determine the fluorescence of individual cells. To start, the enriched 
population was combined with serum and a fluorescent secondary antibody that bound to the 
constant region of IgG antibodies. Cells displaying only the protein eCPX were used to 
establish the background level of expression. Then, we measured the fluorescence of the 
enriched library above the background level of expression. Generally, if the fluorescence 
above background was greater than 50%, the library was prepared for sequencing. Often, the 
enriched population had 80-90% fluorescence above background.  
1.5.3 DNA sequencing 
To extract DNA, we lysed the enriched population cells and collected the plasmids. 
Then, we used PCR to amplify the sequences in the plasmids coding for peptides. To 
multiplex specimens, we assigned a separate barcode to each serum specimen. Next, we 
sequenced the barcoded DNA using the NextSeq 500, usually generating approximately 300-
500 million reads. This translated to approximately 50 million total sequences for 30 
specimens. These DNA sequences were then translated to amino acid sequences. Finally, we 
combined sequences that only differed due to sequencing errors.  
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2 A general approach for identifying protein epitopes targeted by 
antibody repertoires using whole proteomes 
 
Antibodies are essential to functional immunity, yet the epitopes targeted by antibody 
repertoires remain largely uncharacterized. To aid in characterization, we developed a 
generalizable strategy to identify antibody-binding epitopes within individual proteins and 
entire proteomes. Specifically, we selected antibody-binding peptides for 250 distinct sera 
out of a random library (1010 members) and identified the peptides using next-generation 
sequencing. To identify antibody-binding epitopes and the antigens from which these 
epitopes were derived, we tiled the sequences of candidate antigens into short overlapping 
subsequences of length k (k-mers). We used the extent to which each of these k-mers was 
enriched over background in the antibody-binding peptide dataset to identify antibody-
binding epitopes. As a positive control, we used this approach, termed K-mer Tiling of 
Protein Epitopes (K-TOPE), to identify epitopes targeted by monoclonal and polyclonal 
antibodies of well-characterized specificity, accurately recovering their known epitopes. To 
characterize a commonly targeted antigen from Rhinovirus A, K-TOPE identified three 
epitopes recognized by antibodies present in 83% of sera (n = 250). An analysis of 2,908 
proteins from 400 viral taxa that infect humans revealed seven enterovirus epitopes and five 
Epstein-Barr virus epitopes recognized by >30% of specimens. Analysis of Staphylococcus 
and Streptococcus proteomes similarly revealed six epitopes recognized by >40% of 
specimens. These common viral and bacterial epitopes exhibited excellent agreement with 
previously mapped epitopes. The K-TOPE approach thus provides a powerful new tool to 
elucidate the organisms, antigens, and epitopes targeted by human antibody repertoires. 
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2.1 Introduction 
 
Immunological memory allows for rapid antibody responses towards diverse antigens 
long after initial exposure. For example, the adaptive immune response to many vaccinations 
is often sustained throughout an individual’s lifetime [125]. This immunological information 
is archived within the genes encoding B-cell and T-cell receptors along with the 
corresponding receptor structures, but has proven difficult to characterize in a comprehensive 
manner. The ability to more fully interrogate immunological memory could reveal exposures 
to pathogens, commensal organisms, and allergens. Such information has proven useful for 
correlating antibody responses with disease outcomes to design more effective vaccines [6]. 
A detailed record of immune exposures can also facilitate the identification of biomarkers to 
diagnose infectious [3], autoimmune [4], and allergic conditions [41]. Furthermore, the 
capability to broadly characterize antibody repertoires at the epitope level could be used to 
identify conserved pathogen epitopes [42] and tumor specific antigen epitopes [126] to aid in 
therapeutic discovery.  
Immunological memory has been investigated extensively through sequencing the 
variable regions of B- and T-cell receptor encoding genes amplified from circulating cells 
[10]. These methods have proven useful for identifying receptor-encoding genes that 
associate with vaccination [127]. Nevertheless, such genetic information has not generally 
provided insight into the specific environmental antigens and epitopes targeted, unless they 
are known a priori. Furthermore, these methods require large specimen volumes (>10 mL) to 
obtain a sufficient quantity of cells [127]. Thus, there remains a need for methods that 
identify the diverse antigen targets of adaptive immunity. 
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Several methods have been developed to profile the protein epitopes of the secreted 
antibody repertoire [2]. One common approach to epitope mapping is to generate short 
overlapping peptides by tiling candidate antigens. These peptides are then assayed for serum 
antibody reactivity in peptide microarray [23] or bacteriophage display library [28] formats. 
However, because these methods are biased towards specific organisms, they do not enable 
comprehensive or hypothesis-free immune evaluation. One strategy to overcome the 
limitations of tiling experiments is to use fully random peptide libraries [32,38,41]. Here, 
experiments are less biased and methods can analyze epitopes corresponding to a variety of 
organisms and antigens. A disadvantage of microarrays is that they are typically several 
orders of magnitude less diverse than peptide display libraries (e.g. 105 [32] versus 1010 
[41]), limiting the effectiveness with which current methods can achieve epitope discovery 
for low titer antibodies. In random library experiments, epitopes are typically discovered 
using de novo motif discovery by unsupervised clustering [49]. The most widely used 
algorithm for this purpose, MEME, scales approximately quadratically with the number of 
input sequences, making it less useful for analyzing large datasets resulting from next 
generation sequencing (NGS). While full-length antibody-binding peptides can be analyzed, 
the majority of the binding energy is typically derived from just 5-6 amino acids [46], thus 
other amino acids within the peptide will contribute noise. To rectify this problem 
researchers developed the IMUNE algorithm to reduce peptide datasets into statistically 
enriched patterns and cluster these patterns to build motifs [43]. 
A significant challenge for epitope mapping approaches is the association of epitopes 
and motifs with their corresponding antigens. Typically about seven amino acids need be 
specified to unambiguously identify the corresponding antigen within the full database of 
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protein sequences [51]. Because linear stretches in epitopes are typically less than seven 
amino acids in length [17], protein database searches of individual epitopes (such as through 
BLAST [50]) often fail to achieve statistical significance. Using multiple epitope matches 
within a single candidate antigen can increase the confidence of antigen prediction [35,38]. 
However, this method is insufficient for antigens with a single important epitope. To address 
this challenge, we present a general approach for associating epitopes with antigens using 
large peptide datasets. The K-mer Tiling of Protein Epitopes (K-TOPE) algorithm identifies 
epitopes by computationally tiling candidate antigens into k-mers, which are then evaluated 
within large datasets of antibody-binding peptides. Here, we demonstrate the utility of this 
approach by identifying linear epitopes within several prevalent infectious pathogens.  
2.2 Results 
 
To enable the identification of protein epitopes bound by serum antibodies, we 
developed a method that uses a database of antibody-binding peptides to identify epitopes in 
known protein sequences (Figure 2.1). First, we selected peptides binding to an individual 
antibody repertoire within a specimen (serum or plasma) from a bacterial display peptide 
library with 1010 random 12-mer members. Then, we identified antibody-binding peptide 
sequences using NGS. To allow for the manipulation of 205 (3.2 million) k-mers rather than 
full-length peptides, we processed peptides into subsequences and evaluated the enrichments 
of all k-mers of length 5 [43]. Next, K-TOPE tiled candidate antigen sequences, such as from 
a proteome, into overlapping k-mers. K-TOPE used the enrichment values for these k-mers 
to construct an enrichment histogram across the length of each protein sequence. The value at 
each sequence position in the histogram was proportional to the enrichment of k-mers that 
included that position. Epitopes were extracted from the maxima in the histogram and scored 
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based on their area under the curve (AUC). Finally, epitopes were assigned an “epitope 
percentile” based on their rank in a list of scores generated from random proteins. 
 
 
Figure 2.1: K-TOPE determines epitopes by tiling proteins into k-mers. (A) The input to 
the algorithm is a dataset of approximately 106 peptides that were bound by serum 
antibodies. (B) All 5-mers are evaluated for their enrichment in the list of peptides. (C) A 
portion of a protein sequence is tiled into 5-mers which are weighted by their enrichment. 
This determines a “frequency” value for each position in the sequence. (D) The frequency 
value for each position in a protein sequence is plotted as a histogram. Possible epitopes are 
highlighted in pink on the graph. Epitope sequences, area under the curve (AUC) scores, and 
significance percentiles are displayed. 
 
To assess the utility of K-TOPE, we first determined epitopes for monoclonal and 
polyclonal antibodies that bind specific, well-defined epitopes in cMyc, V5, and amyloid 
beta. We spiked these antibodies into serum at a final concentration of 25 nM and then 
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selected and identified binding peptides. K-TOPE identified epitopes that corresponded 
closely to the previously reported epitopes of these antibodies (Figure 2.2). Importantly, the 
enrichment histograms generated by antibodies spiked into background serum or buffer were 
nearly identical (Figure 2.3), suggesting that the noisy serum environment minimally affected 
epitope identification. 
 
 
Figure 2.2: K-TOPE found epitopes for antibodies with known specificity spiked into 
serum. Histograms for antibodies with known specificity against amyloid beta (P05067), 
cMyc (P01106), and V5 (P11207) had prominent epitopes (in pink). (A) K-TOPE analysis of 
amyloid beta determined the epitope VKMDAEFRHD (668-678). This antibody was raised 
to whole protein and is known from literature to have a conformation-specific discontinuous 
epitope that maps to segments EFRHDSGY (673-680) and ED (692-693). (B) K-TOPE 
analysis of cMyc determined the epitope EEQKLISEEDLLRKR (408-422). This antibody 
was raised to AEEQKLISEEDLLRKRRE (407-424). (C) K-TOPE analysis of V5 
determined the epitope PIPNPLLGLDS (96-106). The antibody was raised to 
GKPIPNPLLGLDST (94-107). 
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Figure 2.3: A comparison of histograms generated by K-TOPE when antibodies were 
added to serum or buffer. Histograms were generated for antibodies against cMyc 
(P01106), V5 (P11207), and amyloid beta (P05067). The most prominent peaks were present 
regardless of whether antibodies were added to serum or buffer. This suggests that the 
binding signature of a single antibody was not obscured by the many other antibody 
specificities present in serum. 
To identify “public epitopes” conserved across many individuals, epitopes were 
generated for each specimen individually and then clustered. Given the ubiquity of exposure 
to the upper respiratory pathogen Rhinovirus A, we validated the approach by identifying 
epitopes within its genome polyprotein. Using a unique set of 250 serum specimens, we 
identified epitopes within Rhinovirus A that were targeted by 30% or more of the specimens 
(Figure 2.4A). Of the 250 specimens, 87% exhibited binding to at least one of these 
consensus epitopes (Figure 2.4B). Three of these epitopes were located within positions 570-
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620 (Figure 2.4C), in the antigenic attachment region of VP1. A fourth epitope within the 
VP2 region of the Rhinovirus A genome polyprotein was targeted by 43% of the population.  
 
Figure 2.4: K-TOPE identified four epitopes in the Rhinovirus A genome polyprotein. 
(A) K-TOPE was applied to the Rhinovirus A genome polyprotein (P07210) for 250 
specimens. Histograms for all specimens are shown as rows in a heat map. The specimens 
have been clustered such that specimens that bind the same epitopes are adjacent. Regions 
that contain epitopes are outlined by dotted lines. (B) A table of the percentage of the 
population that bound each epitope. For instance, Epitope 1 is the percentage of specimens 
that targeted “1”, “1+2”, ”1+3”, “1+4”, ”1+2+3”, “1+2+4”, ”1+2+3+4”. (C) The region from 
positions 570-620 is divided into 3 sections that correspond to distinct epitopes. These 
epitopes are consensus epitopes which were present in >30% of the 250 specimens. (D) Bar 
graph showing membership in different epitope groups. For example, a specimen that binds 
epitopes 2 and 3 will belong to epitope group “2+3”. In this population, 87% of the 
specimens bound at least one of the consensus epitopes. The sequences of the epitopes were 
1: QNPVENYI, 2: DSVLEVLVVPN, 3: APALDAAETGHT, and 4: NHTHPGEQG. 
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To assess trends in the population, each specimen was assigned into one of eight 
groups based on which of the three VP1 epitopes were bound (Figure 2.4D). Notably, epitope 
binding was not independent, since the group of specimens targeting all three epitopes was 
44% larger than expected and the group targeting epitopes ‘1+3’ was 50% smaller than 
expected (Table 2.1). The average age of the subset of specimens of known age (n=138) was 
35 years, however, the epitope group targeting all three epitopes had an average age of 17, 
and the epitope group targeting none of the epitopes had an average age of 50 (Table 2.2). 
Thus, people who targeted fewer Rhinovirus A epitopes tended to be older. 
Table 2.1: The expected and actual membership of different epitope groups. The 
expected membership of epitope groups was calculated by multiplying the proportions of the 
population that bound each epitope. For example, if epitope 1 was bound by 32% of the 
population and epitope 2 was bound by 67%, then the expected membership of epitope group 
‘1+2’ would be 21%. Note that specimens in groups only bound the epitopes in the groups 
e.g. specimens in group ‘1’ did not bind ‘2’ or ‘3’. Generally, the actual and expected 
membership values agreed except for the ‘1+2+3’ group which had higher membership than 
expected and the ‘1+3’ group which had lower membership than expected (in bold). 
Group Actual Expected Percent Difference 
1 16 17 -6% 
2 72 75 -4% 
3 21 19 11% 
1+2 35 35 0% 
1+3 4 8 -50% 
2+3 34 38 -11% 
1+2+3 26 18 44% 
None 42 37 14% 
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Table 2.2: The average age for each epitope group. The average age for the 138 specimens 
for which there was age data was 35. The ‘None’ group had an average age of 50 which was 
notably higher than the average age of 35 (in bold). Additionally, the ‘1+2+3’ group had a 
lower average age of 17 (in bold). This discrepancy suggests that older people targeted fewer 
Rhinovirus A epitopes. 
Group Average Age Group Size 
1 29 ± 24 6 
2 23 ± 25 35 
3 37 ± 23 11 
1+2 21 ± 21 14 
1+3 39 ± 18 2 
2+3 26 ± 24 20 
1+2+3 17 ± 12 11 
None 50 ± 22 19 
All Specimens 35 ± 27 138 
 
Next, we investigated the utility of using K-TOPE to identify epitopes within a set of 
2,908 proteins from 400 viral taxa with human tropism. This approach yielded 29 epitopes 
that were bound by at least 30% of all specimens (Table 2.3). The prevalence of each epitope 
is noted, which is defined as the proportion of specimens that bound the epitope. Some of 
these epitopes have been reported previously [21,42,128,129], while a few were likely due to 
false discovery (e.g., Mayaro virus and Lyssavirus). Thus, a modest number of prominent 
linear viral epitopes were bound by >30% of the specimens analyzed. A common antigen 
identified from this analysis was Epstein-Barr nuclear antigen 1 (EBNA1) from Epstein-Barr 
virus (EBV), which is expressed in EBV-infected cells [130]. Additionally, the epitopes 
identified for the enterovirus genus were consistent with the epitopes identified for 
Rhinovirus A, which is a species in that genus (Figure 2.4).  
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Table 2.3: A collection of 29 viral epitopes to which >30% of 250 specimens bound. K-
TOPE was used to analyze 2,908 proteins from viruses with human tropism. This search 
demonstrated that only a few prominent linear viral epitopes were bound by a large portion 
of the population.  
Epitope Protein Taxon Accession Prevalence 
DSVLNEVLVVPN Genome polyprotein Enterovirus P07210 0.668 
PALTAAETG Genome polyprotein Enterovirus Q66575 0.588 
GRRPFFHPV Epstein-Barr nuclear antigen 1 Epstein-Barr virus (strain 
GD1) 
Q1HVF7 0.524 
AGAGGGAGA Epstein-Barr nuclear antigen 1 Epstein-Barr virus (strain 
GD1) 
Q1HVF7 0.516 
KYTHPGEA Genome polyprotein Enterovirus Q82122 0.492 
VRRPFFSD Protein UL84 Human cytomegalovirus P16727 0.452 
NPVERYVDE Genome polyprotein Enterovirus Q82122 0.428 
MVVPEFK DNA-binding protein Human mastadenovirus C P03265 0.428 
EVKLPHWTPT Glycoprotein 42 Epstein-Barr virus (strain 
GD1) 
P03205 0.42 
KPQPEKPK Structural polyprotein Mayaro virus Q8QZ72 0.416 
GGAGAGGAGAGGG Epstein-Barr nuclear antigen 1 Epstein-Barr virus (strain 
GD1) 
P03211 0.412 
ININRPLE Large structural protein Lyssavirus Q9QSP0 0.412 
RPSCIGCKG Epstein-Barr nuclear antigen 1 Epstein-Barr virus (strain 
GD1) 
P03211 0.404 
GAGAGAGGG Packaging protein UL32 Simplexvirus P89455 0.376 
LEEVIVEKTK Genome polyprotein Enterovirus Q82081 0.352 
KHTHPGI Replication origin-binding 
protein 
Human herpesvirus 3 P09299 0.352 
AETGHTNKI Genome polyprotein Enterovirus Q82122 0.344 
YVFPHWITK Envelope glycoprotein gp63 Primate T-lymphotropic 
virus 3 
Q0R5Q9 0.34 
KTTNTTTNT Immediate-early protein 2 Roseolovirus Q9QJ16 0.34 
MAADKPTL Genome polyprotein Murray Valley 
encephalitis virus 
P05769 0.34 
SFIVPEFA Virion membrane protein A16 Orthopoxvirus P16710 0.332 
LVLPHWYMA Cytoplasmic envelopment 
protein 1 
Simplexvirus P89430 0.328 
YVDDMLNDI Large tegument protein 
deneddylase 
Human herpesvirus 6A 
(strain Uganda-1102) 
P52340 0.328 
SSGPKHTQKV Genome polyprotein Enterovirus P03303 0.324 
PVPEFQA Non-structural polyprotein Semliki forest virus P08411 0.316 
VPVTPNIAI Genome polyprotein Hepatitis C virus Q68749 0.304 
LHRPALTA Minor capsid protein L2 Human papillomavirus 
type 34 
P36758 0.304 
EHILNRPTG RNA-directed RNA 
polymerase L 
Crimean-Congo 
hemorrhagic fever 
orthonairovirus 
Q6TQR6 0.304 
GEFIGSE Shutoff alkaline exonuclease Human herpesvirus 8 Q2HR95 0.3 
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We performed a similar analysis for the proteomes of the genera Streptococcus and 
Staphylococcus, which are common bacterial human pathogens with 2,976 and 3,071 
proteins in their respective proteomes. K-TOPE was used with each of these proteomes to 
determine epitopes bound by >30% of a population of 250 specimens, yielding 9 epitopes for 
Streptococcus and 13 epitopes for Staphylococcus (Table 2.4). The epitope LIPEFIG(R) in 
ATP-dependent Clp protease ATP-binding subunit ClpX was the most prevalent 
Streptococcus epitope and second most prevalent Staphylococcus epitope. Therefore, K-
TOPE could not determine which genus generated this epitope. The most prevalent 
Staphylococcus epitope was PTHYVPEFKGS from extracellular matrix protein-binding 
protein emp, which is a known virulence factor [131]. For Streptococcus, the second most 
prevalent epitope was GQKMDDMLNS from the highly antigenic Streptolysin O protein 
[132]. This epitope falls within a 70 amino acid range in Streptolysin O that is known to bind 
antibodies [133]. The sequence “DKP” was present in 5/9 Streptococcus epitopes and the 
sequence “PEFXG” was present in 6/13 Staphylococcus epitopes (Table 2.4). Therefore, 
there are multiple candidate antigens that may correspond to these highly enriched 
sequences. 
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Table 2.4: Epitopes in the proteomes of the genera Staphylococcus and Streptococcus 
which were bound by >30% of 250 specimens. K-TOPE was used to analyze 2,976 
proteins from Streptococcus and 3,071 proteins from Staphylococcus. 
Epitope Protein Accession Prevalence 
Streptococcus    
LIPEFIGR ATP-dependent Clp protease ATP-binding subunit ClpX P63793 0.512 
GQKMDDMLNS Streptolysin O Q5XE40 0.436 
QIPALDKPL FMN-dependent NADH-azoreductase A4W2Z7 0.416 
IADKPILD UPF0154 protein SSU05_1707 A4VX34 0.392 
TVADKPVA Phenylalanine--tRNA ligase beta subunit Q5XCX3 0.360 
RTPDKPT Agglutinin receptor P16952 0.324 
VVPNIWR Putative 2-dehydropantoate 2-reductase P65666 0.320 
LLNRPIHD CCA-adding enzyme Q5M153 0.320 
TLADKPEF Autolysin P06653 0.308 
Staphylococcus    
PTHYVPEFKGS Extracellular matrix protein-binding protein emp Q2FIK4 0.572 
LIPEFIG ATP-dependent Clp protease ATP-binding subunit ClpX B9DNC0 0.508 
NKPEFSGAT 3-isopropylmalate dehydratase small subunit Q4L7U3 0.436 
NKNNKNNKN Translation initiation factor IF-2 Q4L5X1 0.372 
KLGNIVPEYK Extracellular matrix protein-binding protein emp P0C6P1 0.360 
KLCRICFRE 30S ribosomal protein S14 type Z Q5HM12 0.352 
DFLNRPVD Proline--tRNA ligase Q4L5W5 0.348 
EKNNNNNNNNS Alkaline shock protein 23 Q4L860 0.320 
GVVPNISR UvrABC system protein A Q5HHQ9 0.312 
LIPEFNQV Homoserine kinase Q8CSQ2 0.308 
SPEFLGSQ Undecaprenyl-diphosphatase B9DK59 0.308 
VGINRPTY Putative glycosyltransferase TagX O05154 0.308 
VIPEFNND Peptide chain release factor 2 Q4L4H9 0.300 
The most prevalent epitopes identified through proteome searches were validated by 
comparison to previously reported epitopes. We chose to analyze the viral proteins EBNA1 
from EBV and the Poliovirus 1 genome polyprotein (representing Enterovirus), which were 
present five and seven times, respectively, in Table 2.3. Bacterial proteins chosen for 
validation were Streptolysin O, corresponding to the second most prevalent Streptococcus 
epitope (Table 2.4), and Extracellular matrix protein-binding protein emp, corresponding to 
most prevalent Staphylococcus epitope (Table 2.4). In all cases, K-TOPE found prominent 
peaks in the histograms that corresponded to reported epitopes (Figure 2.5) [21,39,42,129]. 
Additionally, K-TOPE identified an immunogenic region of GA-repeats from positions 100-
350 in the analysis of EBNA1 [23]. We used a nonparametric statistical test to assign 
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significance to the overlap between K-TOPE epitopes and known epitopes. Using this 
method, all epitopes evaluated using K-TOPE had P-values below 0.05 (Figure 2.5D).  
 
Figure 2.5: Epitopes identified through proteome searches were validated using 
literature-reported epitopes. In (A), (B), and (C), a histogram is shown for a single 
specimen with significant peaks (in pink). To the right of the histogram is a heat map for 250 
specimens. For (A), there is a region of antigenic GA-repeats from positions 100-350. The 
table in (D) provides the statistical significance of agreement between literature epitopes and 
K-TOPE epitopes for the labeled peaks in (A), (B), and (C). The UniProt accessions used for 
this analysis were P03211 for EBNA1, Q8NXI8 for extracellular matrix protein-binding 
protein emp, and P03300 for Poliovirus 1 Genome Polyprotein. Statistical tests where 
epitopes with >50% GA content were removed are denoted by an asterisk “*”. All identified 
epitopes had p-values below 0.05. 
 
Peak # Literature K-TOPE Prevalence P-Value References 
1 KRPSCIGCK RPSCIGCKG 0.40 0.0056* [42] 
2 RRPFF PGRRPFFHP 0.52 0.0031 [21] 
3 VPEFKGSLP PTHYVPEFKGS 0.57 0.019 [39] 
4 PALTAVETGATNPL EIPALTAVETG 0.39 0.003 [129] 
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2.3 Discussion 
 
Here, we present a generalizable methodology for identifying epitopes within 
candidate immunogenic proteins. By tiling proteins into k-mers and evaluating those k-mers 
in a database of antibody-binding peptides, we determined epitopes for individuals and a 
population. One of the main features of this approach is that it combines k-mers to determine 
composite epitopes that may not explicitly exist in the peptide dataset. Another important 
element is using an antigen sequence to identify epitopes, thereby surmounting the 7 amino 
acid requirement for successful antigen identification [51]. 
The K-TOPE approach to epitope mapping differs from reported methods in several 
important ways. First, using a library that contains peptides spanning all viral proteomes 
cannot easily be extended to much larger bacterial or parasitic proteomes [28]. A 
disadvantage of microarrays is that they have far lower 5-mer coverage (~27% [35]), than 
surface display (~100%) which could limit the application of k-mer approaches. Other 
algorithms have been developed that identify binding motifs in peptide datasets, but they lack 
the integrated capability to connect motifs to protein antigens [54,56]. Also, the direct 
method of aligning peptides to sequences becomes computationally infeasible with a large 
number of peptides and candidate antigens [134]. 
The heterogeneity of experimental approaches complicates the validation of putative 
epitopes and their associated antigens. The Immune Epitope Database (IEDB) has an all-
inclusive representation of information [135], which may not reflect important distinctions in 
experimental platforms, specimens, and data analysis techniques. For instance, there are 
likely numerous false positive epitopes for highly studied organisms and few identified 
epitopes for less studied antigens. Also, there is a lack of quantitative data reported for 
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epitopes [136], such as the proportion of a given population that binds an epitope. To address 
this lack of information, we used K-TOPE to analyze specimens for responses to common 
pathogens in a general population. This allows newly identified “public epitopes” to be 
benchmarked by nearly any set of serum specimens. We determined public epitopes in 
Rhinovirus A and showed that people who targeted fewer Rhinovirus A epitopes tended to be 
older, perhaps due to immunosenescence [137], reduced pathogen exposure, or a lower 
incidence of rhinovirus infections [138] . With a diverse group of specimens, it was possible 
to confirm that the RRPFF epitope in EBV’s protein EBNA1 is a very commonly targeted 
epitope [21], rather than a multiple sclerosis-specific epitope [23]. Since the specimens used 
in this study were not assayed for responses to pathogens, acute and chronic infections could 
not be readily distinguished from prior infections. It will be valuable to validate this method 
using antibody-binding peptides that reflect acute infection. Additionally, longitudinal 
studies could aid the identification of epitopes which appear upon vaccination or acute 
infection [9].  
 K-TOPE provides a new tool for identifying diagnostic biomarkers, vaccine 
components, and candidate therapeutic targets. This approach could be used in the iterative 
process of designing a vaccine, since it would be useful to know which epitopes are elicited 
in a population by vaccination. Vaccine formulation could be altered to maximize the 
percentage of the population that targets epitopes associated with a positive disease outcome 
[6]. K-TOPE could also enable the development of diagnostics that assign disease based on 
the presence of epitopes. Since this method only involves a single experimental screen, in 
principle multiple diseases could be simultaneously diagnosed [34]. By searching for 
consensus epitopes in a disease group that are absent in a control group, K-TOPE could 
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discover disease-specific epitopes. For an autoimmune disease, the entire human proteome 
could be analyzed to determine autoantigen epitopes [21]. Similarly, using clinical histories 
of viral infection, K-TOPE could analyze the proteomes of suspected pathogens to link 
epitopes to infections [28]. With specimens that have HLA information, it could be possible 
to detect a correlation between HLA type and bound epitopes [139]. This could have 
implications for how we determine genetic predisposition to immunological disease.  
There are important limitations to the conditions in which this approach could be 
successful. First, this approach is currently limited to the identification of linear epitopes. 
However, since 85% of epitopes have at least one linear stretch of five amino acids [17], 
conformational epitopes with linear segments may be represented in the datasets. This report 
focuses on epitopes from common pathogens which are high-titer, but it could be difficult to 
detect rare antibody epitopes. Methods that selectively deplete out high-titer antibodies could 
prove effective for probing rare antibodies [140]. Another limitation is that protein sequences 
tend to have a large degree of conservation and redundancy [141], as demonstrated by the 
Enterovirus epitope PALTAVETGATNPL [129]. As another example, the Human 
herpesvirus 6A epitope YVDDMLNDI (Table 2.3) contains “DDMLN”, which is shared by 
the Streptococcus epitope GQKMDDMLNS (Table 2.4). Generally, if an epitope sequence is 
present identically in multiple antigens, all candidate antigens should be considered equally 
plausible without further biological or epidemiological information.  
In summary, the present approach enables the discovery of epitopes within the 
proteomes of any organism whose sequence is deposited into the protein database. The 
challenge of associating epitopes with antigens can be surmounted by transforming sets of 
antibody-binding peptides to k-mers and tiling proteins of interest. Advancements upon this 
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paradigm may enable comprehensive immunological evaluations from serum and other 
biological tissues. 
2.4 Materials and methods 
 
2.4.1 Strains and reagents  
E. coli strain MC1061 was used with surface display vector pB33eCPX for all library 
screening experiments. Protein A/G magnetic beads were from Thermo Scientific Pierce. 
Antibodies with known specificity included C3956 rabbit anti-c-Myc polyclonal antibody 
(Sigma), anti-beta amyloid 1-42 antibody [mOC31] - conformation-specific (ab201059) 
(Abcam), and rabbit V8137 Anti-V5 polyclonal antibody (Sigma). Antibodies were spiked 
into healthy donor serum at a concentration of 25 nM. All sera (n=251) were obtained as 
deidentified specimens from biobanks according to institutional guidelines, (Biosafety 
authorization numbers #201417, #201713), and handled according to CDC-recommended 
BSL2 guidelines.  
2.4.2 Bacterial peptide display and sequencing 
The bacterial peptide display screening protocol was carried out as previously 
described [43,124]. Briefly, an E. coli library displaying approximately 8 billion different 12-
mer peptides was combined with 1:100 diluted serum. We used magnetic selection with 
Protein A/G beads to isolate bacterial cells with bound antibodies. Then, we confirmed that 
this isolated fraction of bacteria bound antibodies using flow cytometry. Amplicons were 
prepared from the isolated fraction for sequencing using the Illumina NextSeq. 
41 
 
2.4.3 Protein databases 
Protein sequences were obtained from UniProt or by using the Biopython module 
[142]. Accessions for proteins are noted in figures and figure captions. For the epitope 
validation, accessions were chosen that reference the most highly annotated version of the 
proteins identified in Table 2.3 and Table 2.4. The list of random proteins used for statistical 
analysis was obtained through a UniProt search of “reviewed:yes”. The viral proteome search 
used a Uniref search of “uniprot:(host:"homo sapiens" reviewed:yes fragment:no) AND 
identity:0.9” and yielded 2,908 proteins. The Staphylococcus proteome search used a Uniref 
search of “uniprot:(taxonomy:"Staphylococcus [1279]" fragment:no reviewed:yes) AND 
identity:0.9” and yielded 3,071 proteins. The Streptococcus proteome search used a Uniref 
search of “uniprot:(taxonomy:"Streptococcus [1301]" fragment:no reviewed:yes) AND 
identity:0.9” and yielded 2,976 proteins. 
2.4.4 Selection of literature epitopes 
 For EBNA1, RRPFF was chosen because it was noted that RRPFF antibodies occur 
with equal frequency in the serum of MS and healthy individuals [21]. KRPSCIGCK was 
noted as an EBNA1 epitope that was preferentially targeted by pre-eclamptic women, but 
was also targeted by healthy controls [42]. The motif XPEFXGSXX was discovered and 
inferred to correspond to VPEFKGSLP in Staphylococcus aureus using protein database 
searches [39]. For Poliovirus 1, the epitope PALTAVETGATNPL was found to be a cross-
reactive epitope in many enteroviruses [129]. 
2.4.5 Sequence processing 
 The algorithms for generating nonredundant sequence lists from FASTQ files, 
outputting enrichment values for subsequences, and exhaustively calculating k-mer statistics 
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were adapted from IMUNE [43]. We added the capability to start with lists of peptides rather 
than NGS data. The enrichment of a k-mer is defined as the ratio of the number of 
observations of the k-mer to the “expected” number of observations. The “expected” value is 
calculated as the product of the total number of sequences, the number of frames the k-mer 
could fit in the sequences, and the probability of the k-mer appearing based on amino acid 
usage. If a k-mer’s enrichment is above the “enrichment minimum” (2.0 for this study), it is 
used in K-TOPE. K-mers need to be calculated only once per specimen. All interaction with 
IMUNE-derived code is through a Python module which sets up a folder hierarchy and acts 
as a wrapper for IMUNE-derived code. These programs are memory and hard-drive intensive 
and it is recommended to have at least 16 GB of free RAM and 100 GB of hard-drive space. 
Analysis was carried out on a Dell Optiplex 9020 with an Intel® Core™ i7-4790 CPU @ 
3.60 GHz, 64-bit operating system, and 32.0 GB of RAM. Processing FASTQ files into 
subsequences from 12 specimens, each containing approximately 1.5 million unique 
sequences, required 2.3 hours and calculating k-mer enrichment required 7.7 minutes. The 
duration of these calculations scales approximately linearly with the number of specimens 
and sequences. 
2.4.6 K-TOPE algorithm 
 The K-TOPE algorithm is written in Python 3.6 and will be available online. First, 
there is a RAM-intensive step of loading k-mer enrichment data into memory as a dictionary. 
The enrichment dictionary for 250 specimens required approximately 4 GB of RAM. Then, a 
protein of interest is chosen for analysis and its sequence is loaded. This protein is tiled into 
k-mers of a set length. For this study, 5-mers were used. Each position in the protein 
sequence is assigned a frequency counter that starts at 0. The frequency counter of each 
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sequence position contained in an enriched k-mer is incremented by the logarithm base 2 of 
the k-mer’s enrichment. The frequency counters are compiled into a histogram which is 
smoothed using a moving window. For this analysis, the window had width 7 and used linear 
weighting with 1 in the center and 0.1 at the edges. Minima and maxima are identified in the 
smoothed histogram. All intervals between 2 minima that contain a maximum are used to 
define epitopes. Epitopes were limited to a minimum length of 6 and a maximum length of 
15. Epitopes are scored using the area under the curve of the un-smoothed histogram. To 
assign statistical significance to each epitope, the epitope’s score is ranked in a list of scores 
for epitopes of the same length generated through an analysis of 10,000 random proteins. 
This rank is reported as a percentile in the distribution of random protein epitope scores. For 
this study, a percentile cutoff of 95% was used. For 12 specimens, analysis of 10,000 random 
proteins required 10.0 minutes.  
 After determining epitopes for individual specimens, K-TOPE can determine 
consensus epitopes for a population. Each epitope is characterized by a “centroid” which is 
the weighted central position of the epitope, indexed as a position in the protein sequence. 
Centroids for all epitopes that meet the percentile cutoff are compiled. They are then 
clustered using k-means to associate close centroids with the KMeans function from scitkit-
learn [143]. A representative epitope is made for each cluster and kept if it meets a minimum 
prevalence in the population. Closely overlapping epitopes are removed and the final list is 
sorted by prevalence. Consensus epitopes can be determined for each protein in a proteome, 
generating a list of epitopes prevalent in a population. Determination of consensus epitopes 
for the Rhinovirus A genome polyprotein (P07210) for 250 specimens required 24.4 seconds. 
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The proteome searches for viruses with human tropism, Staphylococcus, and Streptococcus 
for 250 specimens required 3.1, 2.3, and 1.9 hours, respectively. 
 We calculated expected membership of epitope groups by multiplying the proportions 
of the population that bound each epitope. For example, if epitope 1 was bound by 32% of 
the population and epitope 2 was bound by 67%, then the expected membership of epitope 
group ‘1+2’ would be 21%. We ranked the overlaps between K-TOPE derived epitopes and 
literature epitopes in a list of 10,000 randomly generated epitope overlaps to determine a p-
value. To remove redundant epitopes found in the proteome searches, we used the PAM30 
similarity matrix to align two epitopes and compare each position to calculate a similarity 
score. Epitopes that had similarity scores >10, were in the same protein, and were from 
different organisms were considered redundant. We removed the less prevalent of the two 
redundant epitopes.  
2.4.7 Data visualization 
 Figure 2.1 was created using Inkscape. Histograms and heat maps were generated 
using the Matplotlib python module [144]. Bar graphs were generated using GraphPad Prism 
7 Software. 
2.5 Supplemental analysis of K-TOPE  
 
2.5.1 Formal statement of the epitope identification problem 
The process of identifying epitopes with K-TOPE requires the following inputs: 
𝑹𝑹: {𝑅1, 𝑅2, … , 𝑅𝑛} is a set of sets of antibody-binding peptides  
 𝑛 ~ 1 − 250 different specimens  
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𝑹𝑛 ∶ {𝑟1, 𝑟2, … , 𝑟𝑙} is a set of antibody-binding peptides  
𝑙 ~ 106 different peptides 
𝒓𝒍 ∶ {𝑐1, 𝑐2, … , 𝑐𝑚} is a string of amino acids  
𝑚 = 12 amino acids  
𝑷: {𝑃1, 𝑃2, … 𝑃𝑞} is a set of protein sequences  
𝑞 ~ 1 −  5,000 different proteins 
𝑷𝒒: {𝑐1, 𝑐2, … , 𝑐𝑣} is a string of amino acids  
𝑣 ~ 100 − 3000 amino acids 
Using these inputs, the following outputs are generated: 
𝑬: {𝐸𝑛𝑞1, 𝐸𝑛𝑞2, … , 𝐸𝑛𝑞𝑖} epitopes for specimen 𝑛 and protein 𝑞 
 𝑖 ~ 0 − 10 epitopes 
𝑬𝒏𝒒𝒊: {𝑐𝑠, 𝑐𝑠+1, … , 𝑐𝑡} amino acids which are a subsequence of protein 𝑞 and  
meet the constraints 1 ≤ 𝑠 ≤ 𝑡 ≤ 𝑟 and 6 ≤ |𝑡 − 𝑠| ≤ 15 
𝑺: {𝑠𝑛𝑞1, 𝑠𝑛𝑞2, … , 𝑠𝑛𝑞𝑖} scores for specimen 𝑛, protein 𝑞, and epitope 𝑖 
 𝑠 ≥ 0 
𝑹𝑺: {𝑟𝑠1, 𝑟𝑠2, … , 𝑟𝑠𝑣} scores for epitopes generated from 𝑣 random proteins 
 𝑣 = 10,000 
𝑷𝑺: {𝑝𝑠𝑛𝑞1, 𝑝𝑠𝑛𝑞2, … , 𝑝𝑠𝑛𝑞𝑖} percentiles for specimen 𝑛, protein 𝑞, and epitope 𝑖 
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 Each epitope 𝐸𝑛𝑞𝑖 has its score 𝑠𝑛𝑞𝑖 ranked in 𝑹𝑺 to determine 𝑝𝑠𝑛𝑞𝑖  
 0 ≤ 𝑝𝑠 ≤ 100 
𝑪𝑬: {𝑐𝑒𝑞1, 𝑐𝑒𝑞2, … , 𝑐𝑒𝑞𝑢} consensus epitopes for protein 𝑞 
𝑪𝑬𝑺: {𝑐𝑒𝑠𝑞1, 𝑐𝑒𝑠𝑞2, … , 𝑐𝑒𝑠𝑞𝑢} scores for epitopes in 𝑪𝑬 
𝑪𝑬𝑷: {𝑐𝑒𝑝𝑞1, 𝑐𝑒𝑝𝑞2, … , 𝑐𝑒𝑝𝑞𝑢} prevalence values for epitopes in 𝑪𝑬 
Thus, the goal of epitope identification is to develop a mapping from the peptide set 𝑹𝑹 to 
the protein set 𝑷 to identify epitope sets 𝑬 and 𝑪𝑬. The epitope set 𝑬 has an associated score 
set 𝑺 and percentile set 𝑷𝑺. The consensus epitope set 𝑪𝑬𝑺 has an associated score set 𝑪𝑬𝑺 
and prevalence set 𝑪𝑺𝑷. 
2.5.2 Evaluating the contributions of overlapping k-mers 
 Many epitopes are dominated by a single highly enriched “core” k-mer, such as in the 
case of “GRRPFFHPV” from EBNA1 (Figure 2.5A) where the average enrichment of 
“RRPFF” for 250 specimens was 299. The next most enriched k-mer in this epitope was 
PFFHP with an average enrichment of 87. Therefore, it is reasonable to question how much 
additional information is contributed by the k-mers surrounding the core k-mer. This 
question can be addressed by examining two epitopes that share a highly enriched core k-
mer. In this case, the surrounding k-mers will determine which epitope has a higher score or 
prevalence. For example, the epitopes GRRPFFHPV in EBNA1 and VRRPFFSD in Protein 
UL84 of human cytomegalovirus (CMV) (Table 2.3) both share the core k-mer RRPFF. 
However, the EBNA1 epitope had a prevalence of 0.524 and the Protein UL84 epitope had a 
prevalence of 0.452. Therefore, the inclusion of the k-mers surrounding RRPFF led to a 
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higher prevalence for the EBNA1 epitope than for the Protein UL84 epitope. The average 
enrichment for each k-mer that composes the EBNA1 and Protein UL84 epitopes is 
displayed in Figure 2.6. For the EBNA1 epitope, the surrounding k-mers were more highly 
enriched than for the Protein UL84 epitope. We can infer that the antigen with the higher 
prevalence epitope is the more plausible origin of the RRPFF-containing epitope. By this 
argument, the more plausible source of the RRPFF-containing epitope is EBNA1. Thus, the 
k-mers surrounding the core k-mer contributed significant information and can be used to 
determine which antigens are more plausible. 
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Figure 2.6: Comparison of RRPFF-containing epitopes in EBNA1 and Protein UL84. 
(A) The enrichment of k-mers comprising the EBNA1 epitope. (B) The enrichment of k-mers 
comprising the Protein UL84 epitope. The k-mers surrounding RRPFF in EBNA1 are more 
highly enriched than the k-mers surrounding RRPFF in Protein UL84. 
 
2.5.3  Assessing the validity of combining adjacent k-mers to determine epitopes 
To further explore the validity of combining information from overlapping k-mers, 
we calculated the correlation between the enrichments of adjacent k-mers. We assumed that 
if adjacent k-mers were similarly enriched for a set of specimens, then they were part of the 
same epitope. This analysis used the Rhinovirus A genome polyprotein, for which prevalent 
A B 
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epitopes were identified earlier (Figure 2.4). We tiled the Rhinovirus A genome polyprotein 
into 5-mers and calculated the enrichment of each 5-mer in 250 specimens. Then, enrichment 
values were normalized to 0 or 1 depending on whether the values were above the 95th 
percentile, ranked in the list of all 5-mer enrichments. Thus, each 5-mer was associated with 
a set of 250 binary scores (one for each specimen). Then, we calculated the correlation 
between each 5-mer’s set of binary scores with all other 5-mer score sets. To determine 
regions of correlated 5-mers, we used a moving window approach where we averaged each 
5-mer’s correlation with the correlations of the three preceding and three following 5-mers. 
This analysis revealed 5-mers with enrichments that were highly correlated with adjacent k-
mers (Table 2.5). 
Table 2.5: Top 25 k-mers which were highly correlated with preceding and following k-
mers. There were highly correlated regions from approximately 577-588 and 214-216. 
K-mer position Correlation Average 
588 0.53 
587 0.53 
586 0.52 
585 0.51 
46 0.5 
214 0.5 
579 0.5 
215 0.48 
216 0.48 
584 0.47 
577 0.46 
580 0.46 
47 0.46 
583 0.45 
581 0.44 
  
This analysis showed that there were highly correlated regions from approximately 
positions 577-588 and 214-216. As shown earlier (Figure 2.4), Rhinovirus A epitope 
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QNPVENYI was at positions 573-580, epitope DSVLNEVLVVPN was at positions 581-592, 
and epitope NHTHPGEQG was at positions 213-222. Thus, the regions of highly correlated 
k-mers corresponded closely with the epitopes determined using K-TOPE. The reason for 
this agreement is likely because these k-mers are bound by the same antibodies. Therefore, 
combining consecutive enriched k-mers to determine longer epitopes appears valid. 
2.5.4 Justification of conducting analysis with 5-mers 
We chose to use 5-mers for K-TOPE analysis because they were the optimal k-mer 
length based on library coverage and enrichment dynamic range. Here, library coverage of a 
k-mer is defined as the percentage of all 20k k-mers that are observed at least once in the 12-
mer peptide library before selection. The library coverage percentages of all 12 k-mers is 
presented in Table 2.6.  
Table 2.6: Library coverage for k-mers of varying length. Note that the exact coverage 
for 5-mers is 99.99990625 %, thus only three out of 3.2 million 5-mers were not observed. 
K-mer Length Percentage (%) 
1 100 
2 100 
3 100 
4 100 
5 100.0 
6 96.0 
7 25.0 
8 1.3 
9 5.3E-02 
10 2.0E-03 
11 6.6E-05 
12 1.6E-06 
As shown in Table 2.6, 5-mers were the longest k-mers that still had virtually 
complete library coverage. While 6-mers could still be useful for analysis, they only had 
approximately 96% coverage. To increase coverage of the 6-mers, we would need to 
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construct a larger library, conduct experiments with a larger oversampling of the library, or 
achieve greater NGS sequencing depth. To further illustrate the limitations of using 6-mers, 
we examined the 5-mer and 6-mer coverage after selection for a single specimen. In this set, 
there was 87.7% coverage of 5-mers and 15.1% coverage of 6-mers. The maximum possible 
6-mer coverage for this specimen was 20.3%. Therefore, since K-TOPE analyzes a single 
specimen at a time, 6-mers will not have greater than approximately 20% coverage. In 
summary, to ensure that we avoided sparse datasets we conducted analysis with 5-mers. 
Additionally, the length of a k-mer affects expected observations and therefore affects 
the dynamic range of enrichments. To illustrate, a k-mer with 1 observation and an expected 
value of 1 would have an enrichment of 1. In contrast, a k-mer with 1 observation and an 
expected value of 0.1 would have an enrichment of 10. In the case of low expected values, a 
single observation will lead to a high enrichment. However, a single observation could 
possibly be due to noise. Ideally, the expected value should be of order one such that a single 
observation will not lead to a high enrichment. To identify which k-mer length had an 
expected value of order one, we calculated the expected values for a set of 1.5 million 12-mer 
peptides with equal amino acid frequencies of 0.05 (Table 2.7). The 5-mers were the only k-
mer length with an expected value of order one, with an expected value of around 4. Note 
that the actual expected value varies with the amino acid frequencies and the number of 
sequences. Thus, for 6-mers to have an expected value of order one, we would require 
approximately 10 times more sequences per specimen. Thus, with the current number of 
sequences per specimen, k-mers of length 5 were optimal for K-TOPE. 
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Table 2.7: The expected number of sequences for different k-mer lengths. These 
calculations assumed a total of 1.5 million sequences and equal amino acid frequencies of 
0.05. Only 5-mers have an expected value of order 1. 
K-mer Length Expected 
1 9.0E+05 
2 4.1E+04 
3 1.9E+03 
4 84 
5 3.8 
6 0.16 
7 7.0E-03 
8 2.9E-04 
9 1.2E-05 
10 4.4E-07 
11 1.5E-08 
12 3.7E-10 
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3 Mapping antibody binding using multiplexed epitope substitution 
analysis 
 
A more complete understanding of antibody-binding epitopes would aid the 
development of diagnostics, therapeutic antibodies, and vaccines. However, current methods 
for mapping antibody binding in epitopes require a targeted experimental approach, which 
limits throughput. To address these limitations, we developed Multiplexed Epitope 
Substitution Analysis (MESA) which can rapidly characterize multiple epitopes using 
millions of antibody-binding peptides. We selected peptides from a random 12-mer library 
that bound to human serum antibody repertoires and determined their sequences using next-
generation sequencing (NGS). Next, we evaluated the enrichment of all 5- and 6-mers in the 
peptide dataset. Computationally, we divided target epitope sequences into overlapping k-
mers. Then, the positions in each k-mer were substituted with all 20 amino acids and the 
enrichments of the substituted k-mers were determined in the peptide dataset. This approach 
enabled the identification of substitutions favored for binding at each position in the target 
sequence, revealing the binding motif. To validate MESA, we determined binding motifs for 
monoclonal antibodies spiked into a serum specimen, recovering the expected binding 
positions and amino acid preferences. To characterize epitopes bound by a population, we 
analyzed 50 serum specimens to determine the binding motifs within various target epitopes, 
including known pathogen epitopes. Binding motifs identified by MESA agreed with those 
discovered using alternative computational approaches. MESA’s ability to utilize the depth 
of NGS datasets enabled the identification of an Epstein-barr virus binding motif that was not 
discovered with alternative approaches. These results demonstrate that MESA can rapidly 
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identify binding motifs for multiple epitopes in parallel to enhance our understanding of 
antibody interactions. 
*This chapter was co-authored with Joel D. Bozekowski with equal contributions. 
3.1 Introduction 
The capability to map antibody binding in epitopes has become essential in 
applications ranging from basic research to therapeutic and diagnostic development. For 
example, therapeutic antibody development requires precise determination of epitopes to 
achieve desired biological activity [145] and to avoid undesired cross reactivity [7]. 
Similarly, epitope identification can aid in the development of vaccines that generate 
neutralizing antibody responses [6]. Additionally, the performance of many antibody 
serology diagnostic tests is limited by knowledge of the most sensitive and specific epitopes 
[34]. Finally, the identification of epitopes can yield more effective affinity-capture reagents 
for research [8]. 
While the gold standard for characterizing antigen epitopes is X-ray crystallography 
[146], epitope mapping methods using substitution analysis and peptide libraries have 
become commonplace [2,19]. To determine the extent that each position in an epitope 
contributes to binding, alanine scanning mutagenesis has commonly been employed [28]. 
Extending this approach, exhaustive mutagenesis can be used wherein each position in an 
epitope is mutated to all amino acids [26]. Given the labor-intensive nature of these methods, 
there remains a need for more efficient, high-throughput methods to characterize and map 
antibody binding in epitopes. 
Peptide microarrays have been used extensively to determine antibody specificities 
[44]. In these approaches, the antigen is tiled into overlapping peptides and exhaustively 
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mutated. The importance of each amino acid for antibody binding in the entire protein 
sequence can then be inferred from the extent of antibody binding to each peptide. 
Unfortunately, since this method uses a targeted library, new microarrays must be prepared 
for each protein of interest. For the analysis of many antigens, or antibody specificities within 
unknown antigens, this process becomes impractical. 
To address the limitations of targeted epitope characterization approaches, we 
developed a method termed Multiplexed Epitope Substitution Analysis (MESA), which 
utilizes random peptide libraries, NGS, and bioinformatics to simulate exhaustive 
mutagenesis of arbitrary epitopes. First, we selected antibody-binding peptides from a large 
surface-displayed peptide library. Next, we evaluated the enrichment of all 5-mers or 6-mers 
in the antibody-binding peptide dataset. We then divided target epitope sequences into 
overlapping k-mers and evaluated the enrichments of the k-mers and all possible single-
amino acid substitutions. Through this analysis, we determined the effect of amino acid 
substitution at each position in the epitope to reveal the binding positions and amino acid 
preferences. Since MESA utilizes millions of peptides selected from a random library, many 
protein epitopes can be characterized simultaneously. 
3.2 Results 
 
3.2.1 MESA maps binding in epitopes using random peptide libraries 
MESA characterizes the binding of antibodies to linear targets through random 
peptide library screening. This approach determines the binding motif of a target epitope, 
indicating which positions are conserved or variable and which amino acids are preferred at 
each position. We adapted the algorithm ArrayPitope [44] to use peptide sequences derived 
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from random peptide libraries, rather than microarray binding data. By using random 
libraries, MESA can examine numerous target sequences via substitution analysis to 
determine binding motifs (Figure 3.1). A binding motif can be visually represented as an 
“epitope logo” that reveals amino acid preferences at each position in a target sequence. For 
this approach, large peptide sequence datasets are obtained by enriching a random peptide 
library for serum antibody binding and identifying the enriched peptides using next-
generation sequencing (NGS) [43]. The epitope region of interest (the target sequence) is first 
transformed into k-mer sequences (5- or 6-mers) with one amino acid overlap spanning the 
entire sequence. Then, the enrichment of each k-mer in the antibody-binding peptide dataset 
is calculated. Each position of the overlapping k-mers is substituted with each amino acid 
and the enrichments of the substituted k-mers are calculated to determine the effect of amino 
acid substitution. Finally, the effects of substitution on each k-mer are compiled to determine 
the effects of substitution in the whole target sequence. 
 
Figure 3.1: An overview of Multiplexed Epitope Substitution Analysis (MESA). A 
random peptide library is screened for peptides that bind serum antibodies and the 
enrichments for all k-mers of a set length are calculated. A target epitope is divided into k-
mers with a single amino acid overlap. For each k-mer, the positions are substituted with all 
amino acids to generate 20 variants. Enrichments for all k-mers are then compiled to 
determine statistically significant positions and valid substitutions in the epitope. The amino 
acid preferences for each position in the epitope are displayed in an epitope logo. Positions 
which are not important for binding are blank. 
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3.2.2 Determining binding motifs for monoclonal antibodies with known epitopes 
To validate MESA, we analyzed antibody species with known linear epitopes to 
determine binding motifs. First, two mAbs, anti-cMyc and anti-HA, were spiked into a 
human serum specimen at 200 nM each. The known linear epitopes for anti-cMyc and anti-
HA are EQKLISEEDL and YPYDVPDYA, respectively. We identified 619,527 12-mer 
antibody-binding sequences by screening this specimen. MESA was applied to each linear 
mAb epitope by dividing the epitopes into 5-mers and evaluating 5-mer enrichments in the 
peptide dataset. The results generated by MESA are visually displayed with alignment 
heatmaps (Figure 3.2A,C) and epitope logos (Figure 3.2B,D). The relative frequencies of 
amino acids at each position in the target sequence are displayed in an epitope logo. In an 
epitope logo, the total height of letters at a position represents the position’s importance to 
binding and the heights of individual letters reflects the amino acid preferences. Blank 
positions indicate the position was not statistically significant. MESA also generates a 
regular expression that represents the epitope logo. For each epitope, alignment heatmaps 
were generated to visualize the importance of each position within the k-mers. In an 
alignment heatmap, the substituted and target k-mer enrichments are summed for each 
position in a k-mer. Lower values represent a greater effect of substitution at a position 
because at an insignificant position, all substituted k-mers will have the same enrichment, 
leading to a 20 times higher enrichment total than for a significant position. Additionally, the 
contribution of each k-mer to the epitope logo is proportional to its total enrichment, which 
corresponds to the total of each row. 
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Figure 3.2: MESA determined binding motifs for mAbs. A random bacterial display 
peptide library was screened against human serum spiked with anti-cMyc and anti-HA mAbs, 
each at 200 nM, resulting in 619,527 12-mer sequences. MESA was applied to this dataset to 
generate an (A) alignment heatmap and (B) epitope logo for the cMyc target EQKLISEEDL, 
and an (C) alignment heatmap and (D) epitope logo for the HA target YPYDVPDYA. MESA 
used 5-mers, a 10% score threshold, and a 25% minimum enrichment threshold. In alignment 
heatmaps, the substituted and target k-mer enrichments are summed for each position in the 
k-mers. Lower values represent a greater effect of substitution at a position. For epitope 
logos, the absolute height of letters represents the relative effect of substitution at a position. 
The height of individual letters reflects the binding preference at that position relative to the 
original k-mer. MEME sequence logos (insets) were obtained via MEME analysis of 5,000 
sequences using libraries screened with each mAb. 
 
For the two mAbs tested, MESA identified distinct amino acid preferences at each 
position that were significant for binding. For example, position 8 of the cMyc epitope logo 
(Figure 3.2B) was highly conserved for binding with almost exclusive preference for 
glutamic acid (E), while position 9 was half as conserved with roughly equal preferences for 
aspartic acid (D) and glutamic acid (E). The regular expressions corresponding to the binding 
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motifs were KLxSEE[DE] and [PI]Y[DN][IV] for cMyc and HA, respectively. Repeating the 
analysis with 6-mers showed that epitope logos were sensitive to the k-mer length chosen 
(Chapter 3.5.1). To validate these epitope logos, we determined mAb binding motifs by 
screening each mAb spiked into buffer at 20 nM. After NGS, the 5,000 peptides with the 
highest observations from each library were analyzed using MEME to identify sequence 
logos for each mAb (Figure 3.2B,D insets). While MEME and MESA identified similar 
binding motifs for mAbs spiked into buffer, only MESA could identify binding motifs for 
mAbs spiked into serum. Thus, MESA precisely determined the mAb binding motifs in the 
presence of background serum antibodies. 
3.2.3 Using MESA to identify binding motifs with a single serum specimen 
 When exact antibody targets are unknown, MESA can instead be used with single 
peptides that were enriched for antibody binding. MESA can then reveal epitopes within the 
enriched peptides. We analyzed a single serum specimen, which had 364,411 antibody-
binding peptides. Epitope logos and alignment heatmaps were generated for two of the most 
observed peptide sequences in the library, YADVFEYQYDWP (P1) and 
TWRDWWSKQPFQ (P2) with 1,429 and 611 observations, respectively (Figure 3.3). For 
P1, the regular expression was ADxFEY which, along with the alignment heatmap and 
epitope logo, indicated strong amino acid preferences at all positions except position 3 
(Figure 3.3A,B). MEME analysis of the 5,000 highest enriched antibody-binding peptides 
revealed a highly similar motif (Figure 3.3B inset), suggesting that MESA identified the true 
binding motif for the target peptide P1. Similar success was obtained for P2, which had a 
regular expression of S[WF][KR]xW[FYW] and an epitope logo that was nearly identical to 
the MEME sequence logo (Figure 3.3C,D). Notably, even though the P2 target peptide 
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TWRDWWSKQPFQ contained a tryptophan (W) at position 6, MESA accurately identified 
the preference for phenylalanine (F) and tyrosine (Y) as well. 
 
Figure 3.3: MESA determined binding motifs for antibodies in an individual serum 
specimen. We analyzed two highly enriched antibody-binding peptides using MESA with a 
single specimen dataset containing 364,411 sequences. MESA generated an (A) alignment 
heatmap and (B) epitope logo for the P1 target YADVFEYQYDWP, and an (C) alignment 
heatmap and (D) epitope logo for the P2 target TWRDWWSKQPFQ. MESA used 5-mers, a 
10% score threshold, and a 25% minimum enrichment threshold. MEME sequence logos 
(insets) were obtained via MEME analysis of 5,000 sequences obtained from the specimen 
library. 
 
3.2.4 Identifying binding motifs using multiple serum specimens 
 By using large peptide datasets from multiple specimens, MESA identified binding 
motifs that represented a population. Peptide libraries screened against eight individual serum 
specimens were sequenced to obtain a total of 1x107 sequences. This dataset was sufficiently 
large that MESA could utilize 6-mers for increased resolution relative to 5-mers. Also, this 
analysis used increased parameter stringencies due to the large sequence dataset. We used 
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MESA to analyze the two peptides with the most observations in at least six specimen 
libraries, DPYLPHWSTVEV (P3) and KYAFPQRIFVSS (P4) (Figure 3.4). For P3, MESA 
identified the regular expression as LPHW, with highly conserved residues at positions 4–7 
(Figure 3.4A,B). The epitope logo for P3 agreed with the MEME sequence logo determined 
using all 1,865 sequences present in at least six of the eight libraries. For P4, the regular 
expression was KxxFPQx[IV], in strong agreement with the MEME sequence logo (Figure 
3.4C,D). These results show that MESA accurately characterized the binding of two antibody 
species present in multiple serum specimens. 
 
Figure 3.4: MESA identified binding motifs that were common in multiple specimens. 
Libraries screened against eight individual serum specimens were sequenced to obtain a total 
of 1x107 12-mer sequences. The two peptides with the most observations in at least six 
specimen libraries, DPYLPHWSTVEV (P3) and KYAFPQRIFVSS (P4), were used as 
targets for MESA. MESA generated an (A) alignment heatmap and (B) epitope logo for the 
P3 target DPYLPHWSTVEV, and an (C) alignment heatmap and (D) epitope logo for the P4 
target KYAFPQRIFVSS. Due to the larger sequence dataset in this analysis, MESA used 6-
mers, a 5% score threshold, and a 50% minimum enrichment threshold. To validate the 
MESA binding motifs, we identified motifs using MEME analysis of all 1,865 sequences 
observed in at least six of the eight libraries (insets). 
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To validate MESA with an even larger population of specimens, we analyzed epitope 
sequences from common antigens using 50 specimens (> 1x108 sequences). We utilized 
MESA to generate an epitope logo for the common epitope SGSPPRRPPPGRRPFFHPVG 
from Epstein-Barr virus nuclear antigen 1 (EBNA1) [23] (Figure 3.5A). The regular 
expression generated for this epitope was RRP[FW]FHP, which was highly enriched in 64% 
of the specimen libraries. Here, “highly enriched” signifies that a regular expression had an 
enrichment > 10 in a specimen’s sequence set. The EBNA1 motif RRPFF has been found in 
multiple previous analyses [21,128]. The binding motif for another EBNA1 epitope, 
EADYFEYHQEGGPDGEPDVP [128], was determined using MESA (Figure 3.5B). The 
regular expression for this epitope was ADYxEY, which is the same specificity identified 
with MESA using P1 (Figure 3.3). This motif was highly enriched in 30% of the specimen 
libraries. The third epitope analyzed, VPEFKGSLP, was from extracellular matrix protein-
binding protein emp in Staphylococcus aureus [39]. MESA generated the binding motif for 
this epitope and identified the regular expression VPEFxG[AS], which was highly enriched 
in 92% of libraries (Figure 3.5C). As additional validation, we conducted a MEME analysis 
of 5,000 sequences observed in at least 10 of the 50 specimen libraries. This analysis 
revealed motifs that corresponded to the binding motifs determined with MESA (Figure 3.5 
insets). These analyses demonstrated the power of MESA to efficiently mine large datasets 
for antibody binding characterization. 
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Figure 3.5: Binding motifs of common epitopes were identified using MESA. Libraries 
from 50 specimens (> 1x108 sequences) were analyzed with MESA to determine the binding 
motifs of three common epitopes: (A) the EBNA1 epitope SGSPPRRPPPGRRPFFHPVG, 
(B) the EBNA1 epitope EADYFEYHQEGGPDGEPDVP, and (C) the extracellular matrix 
protein-binding protein emp epitope VPEFKGSLP from Staphylococcus aureus. MESA 
utilized 6-mers, a 2.5% score threshold, and a 50% minimum enrichment threshold for (A) 
and (B), but a 25% enrichment threshold was used for (C) due to the shorter epitope length. 
MEME sequence logos (insets) were obtained via MEME analysis of 5,000 sequences 
observed in at least 10 of 50 specimen libraries. 
 
Importantly, MESA can generate binding motifs for epitopes that are represented in a 
small fraction of the sequences, and would therefore be difficult to discover using algorithms 
like MEME. We utilized MESA to determine the binding motif for another common EBNA1 
epitope, RPQKRPSCIGCKGTHGGTGA [23] (Figure 3.6). We determined the regular 
expression for the binding motif as CIGCR, but we did not identify a corresponding motif 
using MEME. However, we determined CIGCR to be highly enriched in 34% of specimen 
libraries, suggesting that this epitope was bound by a significant proportion of the population. 
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Figure 3.6: An EBNA1 binding motif was discovered using MESA. Libraries from 50 
specimens (> 1x108 sequences) were analyzed with MESA to discover a binding motif for the 
EBNA1 epitope RPQKRPSCIGCKGTHGGTGA. MESA utilized 6-mers, a 2.5% score 
threshold, and a 50% minimum enrichment threshold. MEME was not able to identify a 
corresponding motif due to the limited number of input sequences. 
 
3.3 Discussion 
 
Here, we introduced an algorithm for determining the most important positions and 
amino acid preferences in epitopes, starting from a random peptide library. Notably, this 
method enables the identification of binding motifs for multiple epitopes, avoiding the need 
to bias experiments. MESA computationally substitutes individual positions in an epitope 
and calculates the effects of the substitutions. Positions which are the most affected by 
substitutions are plausibly important to antibody binding. Since our bacterial display library 
has ~100% coverage of 5-mers and ~96% coverage of 6-mers, our approach can utilize k-
mers to precisely evaluate the effect of a substitution in a peptide. It may be difficult to 
correctly identify binding motifs for approaches with smaller libraries, such as microarrays 
with low k-mer coverage [35]. By analyzing known epitopes for mAbs spiked into serum, we 
showed that only a few positions dominated binding for these antibodies. Additionally, by 
analyzing antibody-binding peptides and known pathogen epitopes, we could refine epitopes 
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into shorter motifs representing the most important binding positions. We mainly focused on 
common epitopes from the antigen EBNA1, since Epstein-Barr virus infects over 90% of the 
population [147]. We were able to validate our results by comparison to MEME [49], with 
the exception of the binding motif CIGCR (Figure 3.6). However, the binding motif CIGCR 
was likely genuine, since it was enriched in the specimens’ sequences and has been 
previously reported [42]. A limitation of MEME is that it can only analyze 5,000 sequences, 
which for the single specimen and 50 specimen analyses was 1% and 0.005% of all 
sequences, respectively. Therefore, an advantage of MESA is that it can more thoroughly 
explore the depth of NGS datasets. Another limitation of using MEME to find significant 
positions in a target sequence is that it required the cumbersome process of searching through 
motifs for similarity to the target. In contrast, MESA simply substitutes a target sequence and 
returns the binding motif. 
MESA has significant advantages over other epitope substitution approaches. 
Targeted substitution schemes like ArrayPitope tile peptides from a protein sequence in a 
microarray format, and then mutate individual positions to all other amino acids [44]. The 
main issue with using a non-random library is that experiments must be repeated for each 
additional protein target. While researchers have used random bacteriophage libraries to 
identify epitopes [39], these approaches required separate targeted libraries to map binding in 
epitopes. Non-random libraries can also lead to inaccurate results if serum antibodies have a 
preference towards a variant of a protein sequence. For example, Celiac disease antibodies 
target deamidated gliadin, thus a microarray using the gliadin sequence could miss this 
binding interaction [148]. MESA represents the first algorithm that can multiplex epitope 
substitution using random libraries. With random libraries, there is no need to bias the 
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experimental approach towards a specific antigen, thus, epitopes corresponding to many 
antigens can be analyzed.  
Limitations of MESA are mostly related to its inclusion of noise, a necessary result of 
using large NGS datasets. With large datasets, sequences which are irrelevant to the true 
binding motif are often included, leading to a poor signal-to-noise ratio. Another limitation is 
that this method requires > 105 sequences for the analysis of serum antibodies, though for 
typical NGS datasets, this requirement should not be difficult to achieve [43]. Also, if a 
group of subjects does not have homogenous binding to an epitope, MESA may not generate 
a clear binding motif. 
MESA could be used to map antibody binding in epitopes for the development of 
more effective diagnostics, therapeutics, and vaccines. Generating a binding motif for a 
disease-specific epitope would allow for the optimization of diagnostic peptides [148]. 
Additionally, associating motifs with disease antigens could provide insights into etiology 
[42,149] and lead to the development of antibody therapeutics, such as for cancer [150]. 
MESA could aid the study of broadly neutralizing antibodies for vaccine design and 
therapeutic development in infections such as HIV [151,152]. This approach could also be 
used to improve the development of peptides vaccines [153] enabling a more focused 
immune response. Moreover, there is an increasing need for robust methods capable of 
studying and resolving cross-reactivity in vaccine development [154]. 
 MESA can characterize binding motifs for antibody-binding peptides or known 
protein epitopes. Importantly, MESA has the capability to probe the full depth of large NGS 
datasets. The ability to identify epitopes relating to multiple antigens will likely become 
indispensable to fully interrogating antibody repertoires. 
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3.4 Materials and methods 
 
3.4.1 Bacterial display and sequencing 
The protocol for screening bacterial display peptide libraries was carried out as 
previously described [43,124]. Briefly, we added 1:100 diluted human serum to an E. coli 
display library of 8x109 random 12-mer peptides, and sorted cells with bound antibodies 
through two rounds of magnetic selection using Protein A/G magnetic beads (Thermo 
Scientific Pierce). DNA amplicon libraries were prepared from the enriched library cells for 
sequencing using the Illumina NextSeq. All sera (N=60) were obtained as de-identified 
specimens from biobanks according to institutional guidelines, (UCSB biosafety 
authorization numbers #201417, #201713), and handled according to CDC-recommended 
BSL-2 guidelines. 
3.4.2 Monoclonal antibody spike-in 
Two rabbit monoclonal antibodies (mAbs), cMyc-Tag 71D10 (EQKLISEEDL) and 
HA-Tag C29F4 (YPYDVPDYA) (Cell Signaling Technology), were used for MESA 
analysis of known target sequences. The mAbs were either added to a human serum 
specimen at 200 nM or added to 1x PBST at 20 nM [140]. 
3.4.3 Sequence processing 
We generated non-redundant sequences from FASTQ files and calculated 5-mer and 
6-mer enrichments using an adapted version of IMUNE [43]. Enrichment is defined as the 
ratio of observations of a k-mer to the “expected” observations. The number of “expected” 
observations is calculated by multiplying the number of frames the k-mer could fit in a 12-
mer peptide with the total number of sequences and the probability of the k-mer appearing 
67 
 
based on amino acid usage. For computations with large specimen datasets using 6-mers, we 
sum the enrichments from all specimens for each k-mer. Running these programs requires at 
least 16 GB of free RAM and 100 GB of hard-drive space. Analysis was carried out on a Dell 
Optiplex 9020 with an Intel® Core™ i7-4790 CPU @ 3.60 GHz, 64-bit operating system, 
and 32.0 GB of RAM. Processing FASTQ files into subsequences from 12 specimens (~1.5 
million unique sequences per specimen) and calculating 5-mer and 6-mer enrichments 
required 136 minutes, 10.1 minutes, and 140 minutes, respectively. The duration of these 
calculations scales approximately linearly with the number of specimens and sequences.  
3.4.4 MESA algorithm 
 Multiplexed epitope substitution analysis (MESA) determines binding motifs, which 
show the positions in an antibody-binding peptide that are important for binding and the 
amino acid (AA) preferences at each binding position. A binding motif is displayed as an 
epitope logo in which the effect of AA substitution at a position corresponds to the absolute 
height at that position. Positions with an insignificant contribution to binding have a height of 
zero. The height of individual AA letters indicates the relative importance of an AA at a 
position. 
The approach for determining binding motifs is based on the methodology used in 
ArrayPitope [44]. To start, a sequence with known antibody binding, denoted the target 
sequence, is tiled into k-mers of 5 or 6 AA with a single AA overlap. For each k-mer, one 
position at a time is substituted with all AAs. This results in 100 variants for 5-mers and 120 
variants for 6-mers. The k-mer which corresponds to the native antigen sequence is termed 
the original k-mer. When using multiple specimens, the enrichment of a k-mer is the sum of 
enrichments in all specimens. All the enrichments are normalized by the original k-mer 
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enrichment. The normalized enrichments are used to populate a position-specific scoring 
matrix (PSSM). In a PSSM, columns represent positions in the target sequence and rows 
represent AA substitutions.  
 The average of each column in the PSSM, denoted the score, indicates whether a 
position in a k-mer is conserved (‘N’) or variable (‘X’). The “conservation string” for a k-
mer indicates which positions are conserved (e.g. NXNXN). If a conserved position is 
substituted, antibody binding will diminish, whereas antibody binding is nearly unaffected by 
the substitution of a variable position. A score near 1 indicates that a position has little 
preference for the original AA at that position and is it therefore a variable position. If the 
score is far below 1, this indicates a strong preference for the target sequence AA and it is 
considered a conserved position. Therefore, we use a binary cutoff value on the score, termed 
the score threshold, to determine if a position should be considered conserved or variable. 
The score threshold is determined by generating PSSMs for 1,000 random k-mers and 
compiling their scores into a list. The assumption is that these random k-mers should have all 
variable positions and should thus possess scores approximating random chance. A score 
threshold is chosen using a low percentile (e.g. 5%) of the list of random scores. 
Additionally, a position is considered variable if the sum of enrichments for the 20 variants 
that substitute that position (“the enrichment sum”) is less than the minimum enrichment 
threshold. This threshold excludes spurious results where a position appears conserved 
because the enrichment is too low. The minimum enrichment threshold is defined as a 
percentile in the distribution of all enrichment sums generated from a target sequence. To 
determine a “sequence conservation string”, the conservation string for each k-mer is aligned 
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to the target sequence. If there is at least one k-mer that is conserved at a position in the 
alignment, then that position is conserved in the sequence conservation string. 
To determine the binding motif, a substitution matrix is generated for each position in 
the target sequence. A substitution matrix describes the AA preferences for each position (the 
“substitution position”) in the target sequence. PSSM columns from positions that overlap 
with the substitution position are used to construct a substitution matrix. PSSM columns are 
only included in the substitution matrix if they are conserved in the k-mer. To determine the 
frequency of each AA at a substitution position, we determine the average of each column in 
the substitution matrix and normalize the averages by the sum of all column averages. 
From the substitution matrices, each position in the target sequence has AA frequency 
values. The frequency values are used to generate the relative entropy matrix by applying the 
following formula to each AA frequency: 
𝑒𝑛𝑡𝑟𝑜𝑝𝑦 = 𝑓𝑎𝑎 log2
𝑓𝑎𝑎
𝑢𝑎𝑎
 
3.1 
 
where 𝑓𝑎𝑎 is the frequency of the AA and 𝑢𝑎𝑎 is the usage of the AA in the peptide dataset. 
In the relative entropy matrix, each row corresponds to a position in the initial sequence and 
each column corresponds to one of the 20 AAs. If a position is determined to be variable, it is 
represented by a row of zeros so that it will not appear in the epitope logo. The relative 
entropy matrix is then input into Seq2Logo to generate an epitope logo [155]. Generating the 
relative entropy matrix for the peptide YADVFEYQYDWP (P1) required 0.016 seconds. 
Generating the epitope logo (using Seq2Logo) from the relative entropy matrix required 0.75 
seconds. 
Determining a regular expression allows for a single textual representation of the 
binding motif. To determine the regular expression, each position in the target peptide 
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becomes an ‘X’ if it is variable or is replaced with one or more AAs if the position is 
conserved. AAs are included in the regular expression if they meet a frequency cutoff (0.2 in 
this analysis). Leading and trailing ‘X’s are then trimmed from the regular expression.  
Elements that were adapted from ArrayPitope [44] include dividing a target sequence 
into shorter overlapping subsequences, generating PSSMs and substitution matrices, and 
visualizing the results using Seq2Logo. MESA differs from ArrayPitope by using peptides 
selected from a random library rather than from targeted microarrays, dividing sequences 
into k-mers, using a different statistical approach, and generating an entropy matrix for input 
to Seq2Logo. 
3.4.5 Identifying antibody binding motifs with MEME 
To validate the binding motifs discovered using MESA, the motif discovery 
algorithm MEME [49] was used to determine antibody binding specificities in a set of 
peptide sequences. MEME uses pairwise sequence comparisons in small sequence sets of 
less than about 5,000 members, while MESA utilizes substitution analysis throughout full 
NGS datasets. Although variations in the results from MESA and MEME will exist due to 
differences in algorithms and data input, comparison to MEME is effective for broadly 
confirming antibody binding specificities and assessing MESA performance. 
MEME is not suitable for analyzing large peptide datasets due to run-time constraints. 
Therefore, all MEME analyses were run with a maximum of 5,000 sequences. To identify 
mAb motifs, a random peptide display library was screened against each mAb at 20 nM in 1x 
PBST [140] and sequenced. A minimum motif width of 8 was utilized for the MEME mAb 
analyses. For all analyses of serum antibody motifs, a minimum motif width of 4 was used. 
For 5,000 sequences, MEME analysis required 10.0 ± 1.4 hours. 
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3.5 Supplemental analysis of MESA 
 
3.5.1 Effects of MESA parameter selection on binding motifs 
We examined the effects of varying MESA parameters on binding motifs by examining 
the changes in epitope logos. First, we varied the score threshold, which determines whether 
a given position in a k-mer is conserved. We completed this analysis using both 5-mers and 
6-mers for two mAbs (Figure 3.7). Whereas epitope logos generated using 5-mers changed 
smoothly as score threshold was increased, epitope logos generated using 6-mers changed 
dramatically when slightly varying the score threshold. This suggested that that the mAb 
datasets contained too few sequences for 6-mer analysis. As a result, we concluded that for 
smaller peptide datasets, MESA should be restricted to analysis using 5-mers. 
 
Figure 3.7: Epitope logos generated for monoclonal antibodies with varying score 
thresholds. Epitope logos for anti-cMyc (EQKLISEEDL) and anti-HA (YPYDVPDYA) 
mAbs were determined with MESA using 5-mers and 6-mers. The score threshold was 
varied to observe the effect on epitope logos. MESA was used with a 25% minimum 
enrichment threshold for all analyses. For MESA with 6-mers, the score threshold had a 
significant impact on the epitope logo due to scarcity of 6-mers in this small dataset. For 5-
mers, the epitope logos were largely constant over a wide range of score thresholds. 
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 Another parameter which could affect epitope logos is the minimum enrichment 
threshold required for a position to be deemed statistically significant. If the total enrichment 
at a position does not exceed this threshold, it will be considered a variable position. This 
threshold largely controls for false positive positions, which have low scores (higher 
significance) simply due to the sparsity of k-mers. Epitope logos were generated for the mAb 
datasets using 5-mers while varying the minimum enrichment threshold (Figure 3.8). 
However, the epitope logos were minimally affected unless the minimum enrichment 
threshold was raised above 50%. To observe the effect of the minimum enrichment threshold 
on a larger dataset using 6-mers, we varied the minimum enrichment threshold for the P3 and 
P4 targets from the multiple specimen analysis (n=8) (Figure 3.9). For this larger dataset, 
varying the minimum enrichment threshold had a significant effect on the epitope logos. 
Thus, parameter selection was highly influenced by dataset size.  
 
Figure 3.8: Monoclonal antibody epitope logos generated with varying minimum 
enrichment threshold percentiles. MESA epitope logos for anti-cMyc (EQKLISEEDL) and 
anti-HA (YPYDVPDYA) mAbs were determined using 5-mers while varying the minimum 
enrichment threshold. The minimum enrichment threshold did not have a large impact on the 
epitope logos. A 10% score threshold was used for all analyses. 
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Figure 3.9: Epitope logos were generated for multiple specimens with varying 
minimum enrichment threshold percentiles. MESA epitope logos were determined for 
targets P3 (DPYLPHWSTVEV) and P4 (KYAFPQRIFVSS) from eight specimen libraries 
(1x107 sequences) using 6-mers while varying the minimum enrichment threshold. A 5% 
score threshold was used for all analyses. 
 
*The following section was not co-authored with Joel D. Bozekowski. 
3.5.2 Determining binding motifs for K-TOPE epitopes 
MESA was used to determine binding motifs for the epitopes identified by K-TOPE in 
Chapter 2. Binding motifs were first generated for epitopes bound by the antibodies against 
cMyc, V5, and amyloid beta using a 10% score threshold (Figure 3.10). For V5 and amyloid 
beta, the binding motifs contained 5 positions with clear amino acid preferences. However, 
the binding motif for anti-cMyc did not have a regular expression similar to KLxSEE[DE] 
identified for anti-cMyc earlier (Figure 3.2). This may be because the cMyc antibody used 
for K-TOPE analysis was polyclonal (Figure 3.10A), whereas the anti-cMyc used earlier was 
monoclonal (Figure 3.2). 
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Figure 3.10: Binding motifs identified for 3 antibodies of known specificity. 
Epitope logos were generated for the epitopes (A) EEQKLISEEDLLRKR from cMyc, (B) 
VKMDAEFRHD from amyloid beta, and (C) PIPNPLLGLDS from V5. The regular 
expressions were (A) QXL[IV][SN][ED]EDLXRK, (B) NPL[LM]G, and (C) 
[DNS][ASG]E[FY]R. 
 We also used MESA to determine binding motifs for highly prevalent bacterial and 
viral epitopes (Chapter 2). Due to the large size of the dataset (250 specimens), we used a 
2.5% score threshold to reduce noise. We generated epitope logos (Figure 3.11) for four 
epitopes in the Rhinovirus A genome polyprotein (Figure 2.4). The epitope logos showed that 
these prevalent Rhinovirus A epitopes generally had only 4-7 conserved positions, which is 
consistent with the expectations that approximately 5 positions dominate binding [46]. 
Additionally, this analysis revealed whether each epitope was bound in the beginning of the 
sequence (Figure 3.11A), the end of the sequence (Figure 3.11B and Figure 3.11C), or the 
middle of the sequence (Figure 3.11D). 
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Figure 3.11: Binding motifs identified for four Rhinovirus A epitopes. Epitope logos were 
generated for (A) QNPVENYI, (B) DSVLEVLVVPN, (C) APALDAAETGHT, and (D) 
NHTHPGEQG. The regular expressions were (A) N[PA]VE, (B), EV[LM]VVPN, (C) 
LXXXETGHT, and (D) THPG[ED]. 
 We determined binding motifs for three prevalent viral epitopes (Table 2.3) identified 
by K-TOPE (Figure 3.12). These epitope logos were similar to those presented earlier in the 
chapter (Figure 3.4B, Figure 3.5A, Figure 3.6). This similarity suggests that determining 
binding motifs is robust to using different sets of specimens and target epitopes. The epitope 
logo generated for an EBV epitope (Figure 3.12B) was similar to the epitope logo generated 
for a highly-observed peptide (Figure 3.4B). Thus, this analysis suggested that the highly-
observed peptide contained an EBV epitope. 
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Figure 3.12: Binding motifs identified for three viral epitopes. Epitope logos were 
generated for (A) GRRPFFHPV, (B) EVKLPHWTPT, and (C) RPSCIGCKG. The regular 
expressions were (A) [RH][RK]P[WF]FHP, (B), EVX[LM]PHWXP, and (C) CIGC. 
Finally, we determined binding motifs (Figure 3.13) for three prevalent bacterial 
epitopes identified by K-TOPE (Table 2.4). Position 4 was variable in the epitope logo for 
GQKMDDMLNS (Figure 3.13B) and variable in an alignment of streptolysin O proteins 
from 7 strains. Thus, these results demonstrated that natural variability in an antigen 
sequence is reflected in a binding motif. The epitope logos in Figure 3.13A, Figure 3.13C, 
and Figure 3.5C were similar, yet they were generated from sequences with minimal 
similarity. Since these epitopes all generated similar binding motifs, it is possible that they 
are related to a single antibody specificity. 
 
Figure 3.13: Binding motifs identified for three bacterial epitopes. Epitope logos were 
generated for (A) PTHYVPEFKGS, (B) GQKMDDMLNS, and (C) LIPEFIGR. The regular 
expressions were (A) PEFXG[SA], (B), [KR]XDDMLN, and (C) P[EQ]FXG.  
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4 Identification of disease-specific epitope and antigens 
 
In a multitude of diseases, antibodies contribute to and characterize disease 
progression. Three diseases with prominent antibody responses are age-related macular 
degeneration, herpes simplex virus, and Chagas disease. Identifying disease-specific epitopes 
and antigens would facilitate the prevention, diagnosis, and treatment of these diseases. To 
identify disease-specific epitopes and antigens, we used K-TOPE with disease and control 
specimens. Then, we mapped antibody binding in these epitopes using MESA. With these 
tools, we identified 42 epitopes in candidate AMD autoantigens as well as 53 epitopes that 
tracked with disease progression. Three candidate AMD autoantigens had a clear relation to 
immune or eye-related pathology. Additionally, we identified 30 HSV2-specific epitopes that 
were 100% specific against HSV1 in novel and previously reported antigens. Several 
epitopes were HSV2-specific even though the epitope sequences were in both the HSV1 and 
HSV2 proteomes. For Chagas disease, we identified 222 epitopes in multiple novel and 
previously described antigens. Notably, these epitopes exhibited similarity to four out of the 
seven peptides used in a Chagas-diagnostic assay. We demonstrated that several putative 
Chagas-specific epitopes cross-reacted with a similar parasite. Also, we identified 1,084 
Chagas-specific epitopes in candidate autoantigens. By determining binding motifs, we 
showed that generally only four or five positions in disease-specific epitopes were important 
to binding. Applying this approach to additional diseases with antibody responses could help 
identify medically relevant epitopes and antigens. 
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4.1 Introduction 
Antibody responses play an integral role in the progression of a variety of diseases. 
The ability to identify and characterize antibody responses would aid the prevention, 
diagnosis, and treatment of diseases. A disease can be prevented by rationally designing 
vaccines that elicit potent neutralizing antibodies against a precise epitope [156]. Since 
treatments are often most effective in the earliest stages of disease, the early detection of 
disease-related antibodies in patient sera is crucial for effective treatment [30]. Critically, 
monoclonal antibodies that specifically target an epitope are frequently used therapeutically 
[157]. Thus, interrogating and understanding the humoral response to diseases can achieve 
multiple medical aims. 
K-TOPE identifies disease-specific epitopes which can then be further characterized 
using MESA. These tools use antibody-binding peptides to identify binding signatures that 
differ between disease and control specimens. Examining these differences increases our 
understanding of disease-specific antibody responses. We used K-TOPE and MESA to 
analyze age-related macular degeneration (AMD), herpes simplex virus (HSV), and Chagas 
disease. Applying K-TOPE and MESA to diseases involving human, viral, and parasitic 
targets constitutes a broad validation of these approaches. 
The first disease we analyzed was the degenerative retinal disease AMD, which is the 
leading cause of blindness in the developed world [57]. AMD is classified as “dry” if it 
features geographic atrophy or “wet” if it occurs with abnormal blood vessel growth. Anti-
retinal antibodies have been identified in AMD patient sera, suggesting that this disease has 
autoimmune components [71]. While researchers have used protein microarrays to identify 
autoantigens [80], no study has attempted unbiased discovery of AMD-specific epitopes. 
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Identifying disease-specific epitopes could aid the discovery of a reliable serological 
biomarker that could be used for diagnosis [59]. 
Another disease with antibody responses is the common viral infection HSV, which 
causes cold sores (HSV1) and genital ulcers (HSV2) [83]. Diagnostic discovery generally 
focuses on HSV2, since it synergizes with HIV infections [86]. Particularly, researchers have 
attempted to discover epitopes in glycoprotein G, since it differs substantially between the 
two HSV species [90]. In general, efforts have been limited to identifying epitopes in the 
surface-exposed envelope glycoproteins, using approaches such as microarrays [101]. 
Therefore, it would be novel to identify HSV2-specific epitopes using the entire proteomes of 
HSV1 and HSV2. 
Finally, the protozoan T. cruzi is responsible for Chagas disease, which can lead to 
cardiomyopathy and digestive megasyndromes [102]. Since 30-40% of patients develop 
cardiac and digestive pathology 10-30 years after initial infection, it is important to diagnose 
Chagas disease before these symptoms occur [102]. Since T. cruzi often has coinfections 
with the causative agent of leishmaniasis, L. major, it is necessary to identify antigens and 
epitopes that are not bound by leishmaniasis specimens [123]. Also, Chagas disease has 
autoimmune components [104], which suggests that there could be undiscovered 
autoantigens. A specific well-characterized Chagas disease antigen is trypomastigote small 
surface antigen (TSSA) [110], which has been used in a diagnostic test [108]. Additional T. 
cruzi antigens have been identified and characterized using proteome-derived [24] and 
random [114] libraries. However, there is a lack of studies that have identified autoantigens 
or have shown that Chagas-specific epitopes do not cross-react with L. major.  
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These diseases have not yet been analyzed using approaches with the flexibility and 
breadth of K-TOPE and MESA. Therefore, we applied these approaches to identify novel 
epitopes and antigens.  
4.2 Results 
 
4.2.1 Age-related macular degeneration 
We analyzed AMD specimens that were originally obtained during the Age-related 
Eye Disease study (AREDS) [158]. We had 49 specimens that were classified as having 
either wet AMD, dry AMD, or both types. Of these specimens, 19 were longitudinally 
collected, such that there were specimens before vision loss (initial timepoint) and during 
vision loss (final timepoint). Since drusen size is a major predictor of AMD status [65], we 
had 49 control specimens which had small or medium drusen. The heterogeneity of these 
specimens posed a challenge for analysis. To allow for sufficiently large sample sizes, we 
grouped specimens as either disease or control, ignoring any subgroups. 
Since autoimmunity is generally accepted to be a component of AMD [71], we 
analyzed the human proteome for autoantigen epitopes. First, we divided the specimens into 
a training set (25 disease and 25 control specimens) and a validation set (24 disease and 24 
control specimens). All specimens corresponded to initial timepoints to enable the 
identification of early markers of AMD. To identify epitopes that characterized the full set of 
AMD specimens, we performed a 2-fold cross validation scheme. In this scheme, we 
identified 25 epitopes using the training set that were sensitive and specific in the validation 
set. Then we switched the training and validation sets to identify 28 additional epitopes. 
Finally, we combined the two sets of epitopes, removed any redundancy, and re-evaluated 
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the prevalence and specificity using the full set of specimens. Using this approach, we 
identified 42 epitopes with prevalence > 0.1 and specificity > 0.95 (Table 4.1). Thus, the 
cross-validation scheme resulted in >50% more epitopes than were identified using separate 
training and validation sets. Examining the degree to which each specimen bound the 
epitopes (Figure 4.1) demonstrated that the epitopes were highly specific, though not highly 
sensitive. It is likely that due to the heterogeneity of the specimen set, only low prevalence 
epitopes could be identified. None of the antigens matched autoantigens implicated in other 
autoimmune diseases [159]. However, plausible autoantigens were identified such as Raftlin, 
which regulates B-cell antigen receptor-mediated signaling [160], and eyes absent homolog 
3, which may be involved in the development of the eye [161]. Additionally, Complement 
C4-A was a plausible antigen since it is involved in the antibody-mediated classical cascade 
[162], and because complement plays a central role in AMD pathogenesis [163]. Thus, we 
identified multiple autoantigens with plausible connections to immunological and eye-related 
pathology. 
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Table 4.1: AMD-specific epitopes were identified. A total of 42 epitopes with prevalence > 
0.1 and specificity > 0.95 were identified using a 2-fold cross validation scheme. Plausible 
autoantigens are in bold. 
Epitope Protein Accession Prevalence Specificity 
ESGALVNFL Probable small intestine urate exporter Q9Y2C5 0.184 0.959 
ALVNYT Sideroflexin-2 Q96NB2 0.163 0.959 
ALGGLVNAV Treslin Q7Z2Z1 0.163 0.959 
GGMLVNAV Raftlin Q14699 0.143 1 
PCCFTDLK N-alpha-acetyltransferase 25, NatB 
auxiliary subunit 
Q14CX7 0.143 0.98 
SVWTKTKAA Protein ERGIC-53 P49257 0.143 0.98 
VGNLVNW SID1 transmembrane family member 1 Q6AXF6 0.143 0.98 
GALVND Probable ribonuclease ZC3H12D A2A288 0.143 0.98 
GAAAAAG Four-jointed box protein 1 Q8BQB4 0.143 0.959 
RQAAAASAAEAG Putative PIP5K1A and PSMD4-like protein A2A3N6 0.143 0.959 
ASLVNASI Anillin Q9NQW6 0.143 0.959 
LVNAPY Phospholipid phosphatase 2 O43688 0.143 0.959 
GALVNDE Transcription initiation factor TFIID 
subunit 1 
P21675 0.122 1 
GALVNDE Isoform 4 of Transcription initiation factor 
TFIID subunit 1 
P21675-4 0.122 1 
GELVNAA Amidophosphoribosyltransferase P35433 0.122 1 
GNLVNF Fibronectin type III domain-containing 
protein 8 
Q8TC99 0.122 1 
SLVNAA Lysophosphatidic acid receptor 2 Q9HBW0 0.122 1 
SKEQHLTF Ankyrin-3 Q12955 0.122 1 
GALVNERTV Inactive serine protease PAMR1 Q6UXH9 0.122 0.98 
TKGLQGTTA HemK methyltransferase family member 2 Q9Y5N5 0.122 0.98 
LKGLQP Ubinuclein-2 Q6ZU65 0.122 0.98 
TMPFDGFDH NUAK family SNF1-like kinase 1 O60285 0.122 0.98 
LKEKHIT E3 ubiquitin-protein ligase RNF31 Q96EP0 0.122 0.98 
KESIFP Condensin-2 complex subunit D3 P42695 0.122 0.98 
AFFHPN XK-related protein 4 Q5GH76 0.122 0.98 
ALVNAI Ubiquitin-like protein 7 Q96S82 0.122 0.98 
TVKEAHLTKD TBCC domain-containing protein 1 Q9NVR7 0.122 0.98 
CKERHFV 2-oxoisovalerate dehydrogenase subunit 
alpha, mitochondrial 
P12694 0.122 0.98 
ALVNATE FACT complex subunit SPT16 Q9Y5B9 0.122 0.98 
LVNAQQ Terminal uridylyltransferase 4 Q5TAX3 0.122 0.98 
ALERGLQD Complement C4-A P0C0L4 0.122 0.98 
LKGLQP Putative ATP-dependent RNA helicase 
TDRD12 
Q587J7 0.122 0.98 
LVMGNIIN SID1 transmembrane family member 2 Q8CIF6 0.122 0.98 
GLGPRGLQAT Laminin subunit alpha-5 O15230 0.122 0.959 
TYQSEKPS Eyes absent homolog 3 Q99504 0.122 0.959 
GAAKGLQ Receptor tyrosine-protein kinase erbB-2 P04626 0.122 0.959 
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FTIFPQF ATP-binding cassette sub-family A 
member 13 
Q86UQ4 0.122 0.959 
LDNKTL Guanine nucleotide exchange protein 
SMCR8 
Q8TEV9 0.122 0.959 
FLNEKR Protein phosphatase 1 regulatory subunit 26 Q5T8A7 0.122 0.959 
SLSRGLQV Serine/threonine-protein kinase TBK1 Q9UHD2 0.122 0.959 
SASAAAASAAAA REST corepressor 1 Q9UKL0 0.122 0.959 
SGVTAEK PH domain leucine-rich repeat-containing 
protein phosphatase 1 
O60346 0.122 0.959 
 
 
Figure 4.1: Heat map showing epitopes scores for disease and control specimens. 
The degree to which each specimen bound the 42 AMD-specific epitopes was 
quantified for all 49 AMD disease and control specimens. These epitopes were highly 
specific, but not highly sensitive. 
 
We determined binding motifs with MESA for the plausible autoantigens Raftlin, 
Complement C4-A, and Eyes absent homolog 3 (Figure 4.2). While the epitope logos in 
Figure 4.2A and Figure 4.2B had clearly defined significant positions, the epitope logo in 
Figure 4.2C had few significant positions. The regular expression for the binding motif in 
Figure 4.2C was simply QP, suggesting that this epitope’s low prevalence (0.122) may have 
limited the applicability of substitution analysis.  
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Figure 4.2: Binding motifs for 3 epitopes that had plausible autoantigens. Epitope 
logos were generated using epitopes (A) GGMLVNAV, (B) ALERGLQD, and (C) 
TYQSEKPS. The regular expressions for these binding motifs were (A) AGXLV, (B) 
[RK]GLQ, and (C) QP. 
 
Using the 19 longitudinal specimens, we identified epitopes that were bound at the 
final timepoint, but were not bound at the initial timepoint. First, we compared the initial and 
final timepoint for each specimen individually to identify epitopes. Then, we determined 
consensus epitopes by clustering these 19 sets of epitopes. Through this process, we 
identified 53 epitopes that were only bound by the final timepoint for at least 3 specimens 
(top 10 in Table 4.2). However, these epitopes did not appear to correspond to any plausible 
AMD pathology or match any known autoantigens [159]. 
Table 4.2: Epitopes that were only bound at the final AMD timepoints. We identified 53 
epitopes that were bound by at least 3 final timepoint specimens. Only the 10 epitopes with 
highest prevalence are shown. 
Epitope Protein Accession Prevalence 
ITTTTTSTT CCR4-NOT transcription complex subunit 1 A5YKK6 0.211 
RTTTRTTTTTTPTP Fibronectin type III domain-containing protein 1 Q4ZHG4 0.211 
EYIADLYSA Reticulocalbin-3 Q96D15 0.158 
VELATAEAL Exocyst complex component 3-like protein Q86VI1 0.158 
TTKTPVE C2 domain-containing protein 5 Q86YS7 0.158 
TPFIHNAFK DNA ligase 4 P49917 0.158 
TTSTTSTTI Mucin-5AC P98088 0.158 
TTTTTTTTTGGI Cyclin-L1 Q9UK58 0.158 
IEADKY Brefeldin A-inhibited guanine nucleotide-
exchange protein 2 
Q9Y6D5 0.158 
TTSTTAPT Putative nuclear envelope pore membrane 
protein POM 121B 
A6NF01 0.158 
A B C 
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4.2.2 Herpes simplex virus 
To identify HSV species-specific epitopes, we analyzed 12 HSV2 specimens and 10 
HSV1 specimens. Since these viruses share many of the same proteins in their proteomes 
[87], HSV1 specimens were appropriate controls for HSV2 specimens and vice-versa. We 
did not use cross-validation for these specimens since dividing the small specimen sets into 
training and validation sets would greatly reduce discovery power. To begin, we identified 
species-specific epitopes in glycoprotein G, which varies significantly between the two 
species (Figure 4.3) [89]. There was a single HSV1 epitope, PMPSIGLEE, bound by 40% of 
HSV1 specimens and a single HSV2 epitope, GGPEEFEGAGD, bound by all HSV2 
specimens. This HSV2-specific epitope aligned well with previous epitopes found for 
glycoprotein G2 [90–92] (Table 4.3). Also, this epitope has been validated as an HSV2-
specific diagnostic [93,94]. The HSV1-specific epitope was also similar to the previously 
reported epitope DHTPPMPSIGLE [101]. Interestingly, the two HSV-specific epitopes 
terminated in an identical 7-mer sequence EGAGDGE (PMPSIGLEEEEEEEGAGDGE and 
GGPEEFEGAGDGE) [91]. This suggests that the regions containing these epitopes may be 
evolutionarily or structurally related targets of the immune system. 
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Figure 4.3: K-TOPE identified epitopes for glycoprotein G1 using HSV1 specimens and 
for glycoprotein G2 using HSV2 specimens. For glycoprotein G1, a representative 
histogram for a single specimen is shown in (A) and a heat map for all HSV1 specimens is 
shown in (C). For glycoprotein G2, a representative histogram for a single specimen is shown 
in (B) and a heat map for all HSV2 specimens is shown in (D). There was a single epitope 
identified for each protein. 
 
Table 4.3: Alignment of an HSV2-specific glycoprotein G2 epitope with previously 
reported epitopes. 
 Peptides Reference 
        G G P E E F E G A G D           K-TOPE 
          P E E F E G A G D G E P P E D D D S G [90] 
 P P P P E H R G G P E E F E G A G D G E P P E      [91] 
A P P P P E H R G G P E E F E G A G D G          [92] 
 
To identify candidate HSV species-specific epitopes, we analyzed the HSV1 and 
HSV2 proteomes. We identified 30 HSV2 specific epitopes that were 100% specific with 
prevalence > 30% (Table 4.4). Notably, 11 of these epitopes were present in all HSV2 
specimens. K-TOPE identified a glycoprotein C epitope PRTTPTPPQ with 83% prevalence 
which was contained in a previously identified epitope RNASAPRTTPTPPQPRKATK 
[101]. Also, a glycoprotein B epitope KARKKGTSAL shared the sequence KARKXXT 
with a previously reported epitope KARKRKTKK [101]. A notable observation was that 
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five of the 30 HSV2-specific epitopes contained the sequence RXTP. However, two of the 
antigens that corresponded to these epitopes, envelope glycoproteins H [95] and C [100], 
were well-described antigens. Since proteins on the outside of a virus, such as the envelope 
glycoproteins [97], are more plausible targets, we compiled a list of all epitopes in capsid and 
envelope glycoproteins (Table 4.5). Thus, choosing the most plausible candidate antigens 
was assisted by additional biological information.  
Table 4.4: HSV2-specific epitopes were identified. A total of 30 epitopes were identified 
that were 100% specific against HSV1. 
 Epitope Protein Accession Prevalence 
GGPEEFEGAGD Envelope glycoprotein G P13290 1 
PLYARTTPAKF Tegument protein UL47 P89467 1 
VDSQRLTPGGSVS Tegument protein UL21 P89444 1 
KARKKGTSAL Envelope glycoprotein B P08666 1 
TPLRYACVL Tegument protein UL47 P89467 1 
ANSPWAPVL mRNA export factor P28276 1 
RYSPLHN Envelope glycoprotein B P08666 1 
EAMLNDAR Large tegument protein deneddylase P89459 1 
QRLTPH Large tegument protein deneddylase P89459 1 
LRYTPAGEV Envelope glycoprotein H P89445 1 
RTPSMR Major viral transcription factor ICP4 homolog P90493 1 
LATNNA Small capsomere-interacting protein P89458 0.917 
LRTNNL Ribonucleoside-diphosphate reductase small subunit P69521 0.917 
PRTTPTPPQ Envelope glycoprotein C Q89730 0.833 
HRLYAVVA Inner tegument protein P89460 0.833 
PSTPAMLNLG Ribonucleoside-diphosphate reductase large subunit P89462 0.667 
VTKHTALCAR Large tegument protein deneddylase P89459 0.583 
TRDYAGL Envelope glycoprotein I P13291 0.583 
RLTVAQ Envelope glycoprotein I P13291 0.583 
RSLGIA Protein UL20 P89443 0.583 
IRDLARTFA Thymidine kinase P89446 0.5 
DITAKHRCL Major capsid protein P89442 0.5 
ETPAQPPRY Capsid scaffolding protein P89449 0.5 
VSGITPTQ Tripartite terminase subunit 1 P89451 0.5 
HEELYYGPVS Tegument protein VP22 P89468 0.417 
IQDLAYAIV Ribonucleoside-diphosphate reductase large subunit P89462 0.417 
GPAQRHTY DNA polymerase catalytic subunit P89453 0.417 
YFEEYAYS Envelope glycoprotein B P08666 0.417 
LDDFDL Tegument protein VP16 P68336 0.417 
AARLIDALYAEFLGG Envelope glycoprotein H P89445 0.333 
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Table 4.5: HSV2-specific epitopes in plausible antigens. Since the exterior of the virus is 
more likely to be targeted, we compiled epitopes in glycoproteins and capsid proteins. 
Epitope Protein Prevalence 
GGPEEFEGAGD Envelope glycoprotein G 1 
KARKKGTSAL Envelope glycoprotein B 1 
RYSPLHN Envelope glycoprotein B 1 
LRYTPAGEV Envelope glycoprotein H 1 
PRTTPTPPQ Envelope glycoprotein C 0.833 
TRDYAGL Envelope glycoprotein I 0.583 
RLTVAQ Envelope glycoprotein I 0.583 
DITAKHRCL Major capsid protein 0.5 
ETPAQPPRY Capsid scaffolding protein 0.5 
YFEEYAYS Envelope glycoprotein B 0.417 
AARLIDALYAEFLGG Envelope glycoprotein H 0.333 
 
In contrast to the numerous HSV2-specific epitopes, only 4 HSV1-specific epitopes 
were identified and the highest prevalence achieved was only 40% (Table 4.6). One of these 
epitopes, RIRLPHI, was in the well-described antigen glycoprotein D, and is thus plausibly 
related to virus neutralization [99]. One possible explanation for the discovery of fewer 
HSV1-specific epitopes is that the HSV2 specimens had high IgM levels, whereas the HSV1 
specimens had high IgG levels. Since high IgM levels occur with severe recurrent herpes 
infections [164], we would expect the high IgM HSV2 sera to yield more epitopes.  
Table 4.6: HSV1-specific epitopes were identified. Only 4 epitopes were identified that 
were 100% specific against HSV2. 
Epitope Protein Accession Prevalence 
RIRLPHI Envelope glycoprotein D Q69091 0.4 
PMPSIGLEE Envelope glycoprotein G P06484 0.4 
CAAFVNDYSLV Major capsid protein P06491 0.3 
EMADTFLDT ICP47 protein P03170 0.3 
 
 We sought to determine whether the HSV2-specific epitopes were contained in 
proteins that differed between the HSV species [89]. We determined 8 HSV2-specific 
epitopes with sequences that were contained in both HSV proteomes (Table 4.7). Our 
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analysis suggested that these epitopes were only targeted by HSV2 specimens, despite their 
presence in the HSV1 proteome. Thus, even regions that are conserved between species 
could serve as species-specific targets. 
Table 4.7: Eight HSV2-specific epitopes were also in the HSV1 proteome. 
Epitope Protein Accession Prevalence 
PLYARTTPAKF Tegument protein UL47 P89467 1 
TPLRYACVL Tegument protein UL47 P89467 1 
ANSPWAPVL mRNA export factor P28276 1 
QRLTPH Large tegument protein deneddylase P89459 1 
LRTNNL Ribonucleoside-diphosphate reductase small subunit P69521 0.917 
PSTPAMLNLG Ribonucleoside-diphosphate reductase large subunit P89462 0.667 
YFEEYAYS Envelope glycoprotein B P08666 0.417 
LDDFDL Tegument protein VP16 P68336 0.417 
 
 Binding motifs were determined for three HSV1-specific epitopes and three HSV2-
specific epitopes (Figure 4.4). The regular expression for the PLYARTTPAKF binding motif 
was [YM]XRX[TDL]P (Figure 4.4B). This regular expression contained RXTP, which was 
noted as being present in several HSV2-specific epitopes (Table 4.4). In the epitope logo for 
KARKKGTSAL (Figure 4.4C), the last 6 positions were important to binding. However, the 
K-TOPE epitope KARKKGTSAL overlapped with the Risinger et al. epitope 
(KARKRKTKK) at the first 4 positions [101]. Thus, the epitope logo revealed that the K-
TOPE epitope was not plausibly related to the Risinger et al. epitope. For the HSV1-specific 
binding motifs, approximately 30-45% of the positions in the epitopes were deemed 
insignificant for binding. This result implies that these insignificant positions could 
potentially be mutated without a concomitant decrease in binding. 
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Figure 4.4: Binding motifs were determined for 3 HSV1-specific epitopes and 3 HSV2-
specific epitopes. Epitope logos (A), (B), and (C) correspond to HSV2-specific epitopes. 
Epitope logos (D), (E), and (F) correspond to HSV1-specific epitopes. MESA was used with 
the epitopes (A) GGPEEFEGAGD, (B) PLYARTTPAKF, (C) KARKKGTSAL, (D) 
RIRLPHI, (E) CAAFVNDYSLV, and (F) EMADTFLDT. The regular expressions for these 
binding motifs were (A) GGP[EP]E[WF]E[GC]XG[DR], (B) [YM]XRX[TDL]P, (C) 
KG[TI]SX[LV], (D) I[RM]LPH, (E) CX[AG][FW][IV]ND, and (F) ADTF[LM][DHC]. 
 
4.2.3 Chagas disease 
We identified epitopes that were present in at least 10% of 45 disease specimens and 
no more than 5% of 30 control specimens. Then, we re-calculated the prevalence and 
specificity of these epitopes using a validation set of 45 disease specimens and 30 control 
specimens. Epitopes which didn’t meet the 10% prevalence and 95% specificity thresholds in 
the validation set were removed. 
We first sought to characterize the diagnostically important Chagas antigen, 
trypomastigote small surface antigen (TSSA) [110,111,113,165]. In analyzing TSSA, we 
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identified the epitope ENKPATGEA, which had a prevalence of 0.178 and a specificity of 
0.967 in the validation set. This epitope had significant overlap with previously identified 
epitopes (Table 4.8). Taken together, these three epitopes implied that the core TSSA epitope 
was approximately KPATGE. This was confirmed by the epitope logo (Figure 4.5), which 
has the regular expression [PW]XTGE. 
Table 4.8: Alignment of a TSSA epitope with previously reported epitopes. 
Peptides Reference 
         E N K P A T G E A    K-TOPE 
T S S T P P S G T E N K P A T G E     [24] 
T S S T P P S G T E N K P A T G E A P S Q [110] 
           K P A T G E A P S Q [111] 
 
 
Figure 4.5: Binding motif determined for the TSSA epitope ENKPATGEA. The 
binding motif had a regular expression of [PW]XTGE, which is similar to previously 
reported epitopes. 
 
To identify epitopes and antigens related to the progression of Chagas disease, we 
used K-TOPE with the T. cruzi proteome (10,770 proteins). Through this analysis, we 
identified 222 Chagas-specific T. cruzi epitopes (top 25 in Table 4.9). Notably, there were 11 
epitopes which were targeted by greater than half of the disease specimens. Many of the 
proteins that were identified are known antigens such as Mucin TcMUCII [114,116], trans-
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sialidase [117], dispersed gene family protein 1 (DGF-1) [114,118], and Mucin-associated 
surface protein (MASP) [120–122].  
Table 4.9: The 25 Chagas-specific epitopes with the highest prevalence. A total of 222 
epitopes were identified that were Chagas-specific. *Previously validated antigens 
Epitope Protein Accession Prevalence Specificity 
RAGDKVE Uncharacterized protein Q4DQL9 0.8 0.967 
EAGDKVQG Trans-sialidase, putative* Q4DVK2 0.733 0.967 
AERMRAIE Uncharacterized protein Q4DEQ5 0.644 1 
SRLREIDG Putative mucin EMUCt-4* Q962H7 0.622 1 
SRFREIDG Mucin TcMUCII, putative* Q4D1D0 0.622 1 
SRLREIDGS Mucin TcMUCI, putative* Q4DR54 0.6 1 
APAAGGFGSA Uncharacterized protein Q4D768 0.6 0.967 
RLREIDGS Mucin TcMUCII, putative (Fragment)* Q4D5F8 0.578 1 
PSRLREIDG Mucin-like protein* O61045 0.556 1 
EFRQIDT Uncharacterized protein V5B8U7 0.533 1 
DEGFGWVER 40S ribosomal protein SA Q4CQ63 0.511 1 
LAGGFGEL Trans-sialidase, putative* Q4CWN6 0.489 1 
CAGDKN Uncharacterized protein Q4DLH9 0.467 1 
MRLIDAVAR Uncharacterized protein Q4D0V6 0.467 1 
VAGDKC Uncharacterized protein Q4DT98 0.467 0.967 
IRAFRLIDV Centrin, putative Q4DBB8 0.444 1 
EAGGFGVL Glucokinase 1, putative Q4E4E1 0.444 1 
SGGFGR Mucin-associated surface protein 
(MASP), putative* 
Q4CZA8 0.444 1 
VGGFGTG Succinyl-CoA:3-ketoacid-coenzyme A 
transferase 
Q4D0L3 0.444 1 
KAGGFGNRVV Uncharacterized protein Q4DIM5 0.422 1 
MRQIDEL Prostaglandin F synthase Q4DJ07 0.422 0.967 
RGGFGASA Uncharacterized protein Q4DAX7 0.422 0.967 
KIRAIEA Ribose 5-phosphate isomerase Q4CQE2 0.422 0.967 
FEGGFGS Dispersed gene family protein 1 (DGF-1), 
putative* 
Q4DTA7 0.4 1 
YGGFGAS Acyl-CoA dehydrogenase, putative Q4DLR8 0.4 1 
Of the 39 Chagas-specific motifs identified by the antibody repertoire profiling 
company SerImmune [115], nine were similar to K-TOPE epitopes (Table 4.10). 
Additionally, using K-TOPE, three SerImmune motifs that could not be associated with 
antigens were associated with surface antigen 2 (B13) [119], Mucin TcMUCII, and DGF-1. 
Notably, 81% of K-TOPE epitopes could not be matched to SerImmune motifs, suggesting 
that these epitopes may be novel.  
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Table 4.10: Comparison between SerImmune motifs and K-TOPE epitopes. Of the 39 
SerImmune motifs, 9 were similar to K-TOPE epitopes. The SerImmune motifs and their 
suspected antigens are shown in bold. For some motifs, the list of matching K-TOPE 
epitopes was truncated. Three of the SerImmune motifs were newly associated with putative 
antigens. 
SerImmune Motif Suspected Antigens K-TOPE epitope K-TOPE antigen 
[RK]MRXID  None AERMRAIE Uncharacterized protein   
SRLREIDG Putative mucin EMUCt-4   
SRFREIDG Mucin TcMUCII, 
putative 
 
 
SRLREIDGS Mucin TcMUCI, putative 
ETXIPXE Complement regulatory 
protein, Trans-sialidase, FL-
160-1 epitope, 05M3-like 
kinesin 
PGETKIPSE Trans-sialidase, putative 
  
GETKIPSES Flagellum-Associated 
Protein (Fragment) 
RXSPYX[IL]F  Kinetoplast DNA-associated 
protein 3 
SPYSIFLQE Kinetoplast DNA-
associated protein 3 
PQXQH[ED]  Helicase, putative, 
Phosphatidylinositol 3-kinase 
PEIQHD Uncharacterized protein 
PXXGGFG  None APAAGGFGSA Uncharacterized protein   
SGGFGR Mucin-associated surface 
protein (MASP), putative   
GGFGQE ATP-dependent RNA 
helicase, putative   
DGGFGG Uncharacterized protein 
HYEWA  Lanosterol cyclase, Terpene 
cyclase/mutase family member 
EHYEWAAG Terpene cyclase/mutase 
family member 
GREXDG  Mucin-associated surface 
protein (MASP), 
Trypanothione synthetase-like 
protein 
GREIDD Trans-sialidase, putative 
  
DGREID Glutaminyl cyclase, 
putative 
A[KR]AG[DN]K  None RAGDKVE Uncharacterized protein   
CAGDKN Uncharacterized protein   
KAGDKKR Uncharacterized protein   
VAGNKQ Trans-sialidase, putative 
F[RN]XIN[RQ]  Dynein heavy chain, 
Eukaryotic translation 
initiation factor 3 subunit 8 
EFRQIDT Uncharacterized protein 
  
LREIDRI Uncharacterized protein   
RREIDR Paraflagellar rod protein, 
putative   
FRQIEI Aminoalcohol 
phosphotransferase, 
putative 
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To provide additional evidence that K-TOPE epitopes were Chagas-specific, we 
compared K-TOPE epitopes to an ELISA diagnostic for Chagas disease [116]. Four members 
of the seven-peptide diagnostic panel matched K-TOPE epitopes (Table 4.11). Thus, the 
Chagas-specific epitopes identified by K-TOPE were well-corroborated by previous research. 
Table 4.11: K-TOPE epitopes matched a diagnostic panel of peptides. Four out of seven 
peptides using in a diagnostic ELISA for Chagas disease matched K-TOPE epitopes. The 
ELISA peptides and their antigens are shown in bold.  
ELISA Peptide ELISA Antigen K-TOPE epitope K-TOPE antigen 
APFGQAAAGDKPSPF b13 / Ag2 / CA-2 / PEP2 PSPFGQAAAG Surface antigen 2 (CA-2), 
putative 
EPKSAEPKPAEPKSA TcD / Ag13 AEPKSAEPK Trans-sialidase, putative   
STPAEPKPA Trans-sialidase, putative 
TTNAPSRLREIDGSL Mucin TcMUCII SRLREIDG Putative mucin EMUCt-4   
SRFREIDG Mucin TcMUCII, putative   
SRLREIDGS Mucin TcMUCI, putative   
RLREIDGS Mucin TcMUCII, putative 
(Fragment)   
PSRLREIDG Mucin-like protein 
DSAKGKATGSSAGED Trans-sialidase AKGKATGS Trans-sialidase, putative 
 
Binding motifs were determined for three prevalent Chagas-specific epitopes (Figure 
4.6). The epitope logos showed that for these epitopes, only 4 or 5 amino acids were 
significant, such as GGFG for the epitope APAAGGFGSA.  
 
Figure 4.6: Binding motifs determined for three Chagas-specific epitopes. Epitope logos 
were generated using epitopes (A) EAGDKVQG, (B) RLREIDG, and (C) APAAGGFGSA. 
The regular expressions for these binding motifs were (A) AGD[KR], (B) MRXID, and (C) 
GGFG.  
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To assess the limitations of using separate training and validation specimen sets, we 
performed a 2-fold cross validation scheme. In this scheme, we identified Chagas-specific 
epitopes using a training and validation set, and then switched the training and validation sets 
to identify additional epitopes. Finally, we combined the two sets of epitopes and removed 
any redundancy. Through this analysis, we determined that there was a 2.7% difference in 
the number of epitopes identified using either training set. After combining the two sets, 
there was a 17.1% increase in the number of epitopes (from 222 to 260) as compared to using 
separate training and validation sets. Thus, regardless of which half of the data was used for 
training, most of the epitopes identified were the same. These results suggest that using 
separate training and validation specimen sets, rather than cross-validation, appears to 
sufficiently characterize this dataset. 
Since there is evidence of autoimmunity in Chagas disease [104], we analyzed the 
human proteome (19,603 proteins) for epitopes. This analysis yielded 1,084 epitopes (top 25 
in Table 4.12). By comparing these epitopes and their antigens to known autoantigens, we 
showed that two of the K-TOPE antigens, mi-2b and MDA-5, were implicated in myositis 
[159]. Since there is cardiac involvement in myositis [166], these two autoantigens could 
plausibly exacerbate the cardiomyopathy exhibited in Chagas disease. Although, it is 
important to note that all candidate autoantigens could be investigated since sometimes 
relevant autoantigens show no obvious relation to pathological phenotypes, such as the 
autoantigen topoisomerase in systemic sclerosis [167].  
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Table 4.12: Candidate autoantigens for Chagas disease. Analyzing the human proteome 
revealed 1,084 Chagas-specific epitopes. Only the 25 epitopes with highest prevalence are 
shown. 
Epitope Protein Accession Prevalence Specificity 
SKMRAIDLQ Nesprin-2 Q8WXH0 0.733 0.967 
RAGDKN Protein FAM71B Q8TC56 0.644 1 
ESAQAGDKC DNA replication licensing factor MCM6 Q14566 0.644 1 
GFGAAGGFGGR Keratin, type II cytoskeletal 2 epidermal P35908 0.6 1 
VISAFAGDKD Cerebellin-4 Q9NTU7 0.578 1 
PGGFGS Replication protein A 32 kDa subunit P15927 0.578 0.967 
FPGGFGAA ES1 protein homolog, mitochondrial P30042 0.578 0.967 
SGGFGS Deoxyuridine 5'-triphosphate 
nucleotidohydrolase, mitochondrial 
P33316 0.556 1 
GGGFGGFGS Keratin, type II cytoskeletal 1 P04264 0.556 0.967 
SGGFGS Serine/threonine-protein kinase pim-1 P11309 0.533 1 
AAGGFGRA Putative solute carrier family 22 member 31 A6NKX4 0.511 1 
SGGFGSR Keratin, type II cytoskeletal 4 P19013 0.511 1 
FRQIDSG Ethanolamine-phosphate cytidylyltransferase Q99447 0.511 1 
APAGGFGGFGT Nucleoporin p54 Q7Z3B4 0.511 1 
VKMRGIDF Fructose-2,6-bisphosphatase TIGAR Q9NQ88 0.511 1 
SAKIRAIE Rabenosyn-5 Q9H1K0 0.511 0.967 
VPGGFGVR CTP synthase 1 P17812 0.511 0.967 
VPQAGGFGC Plasma membrane calcium-transporting 
ATPase 3 
Q16720 0.489 1 
SSASGGFGS Nuclear pore complex protein Nup214 P35658 0.489 1 
LSGGFGSR Keratin, type II cytoskeletal 71 Q3SY84 0.489 1 
NRLREIDE Fibrous sheath-interacting protein 1 Q8NA03 0.489 1 
SGGFGAF Zinc transporter ZIP11 Q8N1S5 0.489 1 
RGGFGS 40S ribosomal protein S2 P15880 0.489 1 
AGGFGGGGFGG Keratin, type II cytoskeletal 1b Q7Z794 0.489 0.967 
LAGGFGF Adenylate cyclase type 5 O95622 0.467 1 
 
Patients with Chagas infections often have coinfections with Leishmania major (L. 
major) [123], thus there is a need for a Chagas diagnostic which is specific against L. major. 
Approximately 1000 [168] out of 8300 [169] L. major genes are not found in T. cruzi. Due to 
this considerable genetic similarity (88%), it was important to remove epitopes bound by 
leishmaniasis specimens from the list of Chagas-specific epitopes. To remove Chagas-
specific epitopes that may also be associated with L. major antigens, we used the L. major 
proteome (7,863 proteins) to identify 929 epitopes bound by at least 2 of 12 L. major 
specimens and none of 12 Chagas control specimens. Then, we removed any epitopes from 
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the 222 Chagas-specific epitopes (Table 4.9) that matched the 929 L. major epitopes. 
Through this analysis, we identified 197 epitopes (top 10 in Table 4.13), a reduction of 
approximately 10% from the 222 epitopes identified earlier (Table 4.9). Notably, the 
prevalent epitopes RAGDKVE and APAAGGFGSA (Table 4.9), were removed by this 
analysis. This suggests that seemingly disease-specific epitopes should be validated against 
similar diseases.  
Table 4.13: Chagas-specific epitopes that do not cross-react with L. major. Epitopes 
RAGDKVE and APAAGGFGSA from Table 4.9 were removed in this analysis. Only the 10 
epitopes with highest prevalence are shown. 
Epitope Protein Accession Prevalence Specificity 
EAGDKVQG Trans-sialidase, putative Q4DVK2 0.733 0.967 
AERMRAIE Uncharacterized protein Q4DEQ5 0.644 1 
SRLREIDG Putative mucin EMUCt-4 Q962H7 0.622 1 
SRFREIDG Mucin TcMUCII, putative Q4D1D0 0.622 1 
SRLREIDGS Mucin TcMUCI, putative Q4DR54 0.6 1 
RLREIDGS Mucin TcMUCII, putative (Fragment) Q4D5F8 0.578 1 
PSRLREIDG Mucin-like protein O61045 0.556 1 
EFRQIDT Uncharacterized protein V5B8U7 0.533 1 
DEGFGWVER 40S ribosomal protein SA Q4CQ63 0.511 1 
LAGGFGEL Trans-sialidase, putative Q4CWN6 0.489 1 
 
4.3 Discussion 
 
We have demonstrated that K-TOPE and MESA can be used to identify and 
characterize disease-specific epitopes and antigens. We identified novel and previously 
reported autoantigens for an autoimmune disease (AMD), a viral disease (HSV), and a 
parasitic disease (Chagas disease). Since we could apply these approaches to a broad 
spectrum of diseases, we infer that these methods could be applied to numerous additional 
diseases. Importantly, even researchers without antibody repertoire analysis expertise could 
integrate K-TOPE and MESA into their analytical pipelines to discover disease-specific 
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epitopes and antigens. Thus, these algorithms could greatly enhance the rate at which 
disease-specific epitopes and antigens are discovered. 
Analyzing three different diseases revealed multiple features of this approach that 
could help improve future epitope discovery. The selection of specimens, specifically sample 
size, is extremely important to study design. For AMD, it is likely that we only identified low 
prevalence epitopes because we used specimens in various states of AMD and used 
heterogenous controls. Unfortunately, using a small sample size for the HSV analysis reduces 
the probability that our results will generalize to a larger population. One computational 
technique that can counter sample size limitations is cross-validation [170]. In the case of 
AMD, cross-validation revealed a significant number of additional epitopes. Although the 
effect of cross-validation was less pronounced for Chagas disease which had a larger sample 
size.  
An important aspect of these approaches is that epitopes and antigens need to be 
validated experimentally or using previous studies. Experimental validation could consist of 
spotting antigens on to a microarray or ELISA to determine if they can differentiate between 
disease and control specimens [171]. For HSV and Chagas disease, we validated epitopes 
using previous studies. However, it was difficult to know a priori whether a non-validated 
epitope was novel or spurious. In general, since studies use different specimens, experiments, 
and computational analyses, it is unlikely for the results of two studies to completely 
coincide. An example of these differences was shown in the comparison of motifs identified 
by SerImmune to epitopes identified by K-TOPE. SerImmune used computational techniques 
that could identify motifs corresponding to non-linear and non-protein epitopes [43]. 
Therefore, we would not expect SerImmune motifs to completely agree with K-TOPE 
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epitopes, which are exclusively derived from protein sequences. Using MESA also aids in 
validating epitopes since it can help determine if two epitopes are equivalent. In the case of 
KARKKGTSAL (Figure 4.4C), the regular expression of the epitope suggested that it 
corresponded to a different antibody specificity than the previously reported epitope, 
KARKRKTKK [101]. In discovering epitopes, it is important to realize that the minimum 
prevalence chosen will largely determine how many epitopes are discovered. For instance, 
although there were 929 L. major-specific epitopes and 30 HSV2-specific epitopes, both 
groups had 12 specimens. This difference can be explained by the choice of a minimum 
prevalence of 2 specimens for L. major and 4 specimens for HSV2.  
Biological understanding of a disease can also aid epitope and antigen discovery. Since 
HSV1 and HSV2 are so closely related [87], analyzing both species was critical to 
establishing whether an epitope was truly specific. Unexpectedly, we demonstrated that even 
epitopes present in the conserved regions of both species’ proteomes could be species-
specific. This is likely due to differences in the structure and post-translational modifications 
of the proteins. Knowing that T. cruzi and L. major often cause coinfections [123], we were 
able to identify Chagas-specific epitopes that were not bound by leishmaniasis specimens. 
This example shows that to develop a clinically useful diagnostic, it is often necessary to 
incorporate epidemiological information into a study. 
The approaches used here have advantages over similar epitope identification schemes. 
While proteome-derived peptide libraries have been used to identify disease-specific epitopes 
[21,24], these methods lack the flexibility to examine multiple proteomes. For instance, 
separate libraries would be required to analyze both HSV1 and HSV2. Also, for Chagas 
disease, it would be impractical to construct a non-random library that covers the entire T. 
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cruzi proteome. Using K-TOPE, we were able to identify epitopes towards the parasites T. 
cruzi and L. major using the same experimental procedure. While random libraries have also 
been used to identify disease-specific epitopes [34], it is often difficult to connect these 
epitopes to antigens in a statistically rigorous manner. By integrating epitope and antigen 
identification, K-TOPE automatically associates every epitope with an antigen. Finally, to 
identify important binding positions in an epitope, most approaches construct a separate 
library for each epitope [28,39,44]. With MESA, multiple epitopes are analyzed in silico to 
identify the most important binding positions and amino acid preferences. 
In this study, we identified epitopes and antigens that could be used for a variety of 
medical applications. A collection of disease-specific epitopes could be combined into a 
multi-epitope peptide for vaccination [101]. Or, novel antigens could be used in a 
conventional ELISA to diagnose diseases with high sensitivity [172]. Also, an epitope that is 
known to contribute to a disease’s pathology could be targeted by a therapeutic monoclonal 
antibody [145]. By applying this approach to any of the numerous diseases that involve 
antibody responses, it could be possible to more effectively prevent, diagnose, and treat 
diseases. 
4.4 Materials and methods 
 
4.4.1 Strains and reagents 
All library screening experiments used E. coli strain MC1061 with display vector 
pB33eCPX. All sera (n=301) were obtained as deidentified specimens from biobanks 
according to institutional guidelines, (Biosafety authorization numbers #201417, #201713), 
and handled according to CDC-recommended BSL2 guidelines. We obtained 12 HSV2 
serum specimens from BioreclamationIVT and 10 HSV1 serum specimens from Discovery 
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Life Sciences. The 117 AMD specimens were collected as part of the AREDS study [158] 
and included 49 disease specimens, 49 control specimens, and 19 final timepoint disease 
specimens. The 90 Chagas disease specimens, 60 control specimens, and 12 leishmaniasis 
specimens were collected by the CDC and screened by the antibody repertoire profiling 
company SerImmune. 
4.4.2 Screening and sequencing bacterial peptide display libraries 
Random bacterial peptide display libraries were screened as previously described 
[124]. Briefly, we combined a 12-mer peptide display library with 1:100 diluted serum and 
used magnetic Protein A/G beads (Thermo Scientific Pierce) to sort for library members with 
antibody-binding peptides. We prepared amplicons from the sorted library members and 
sequenced the amplicons using next generation sequencing (NextSeq). The algorithms used 
to identify peptide sequences and evaluate k-mers are outlined in Chapter 2.  
4.4.3 Protein database searches 
We identified protein sequences using UniProt or with the Biopython module [142]. 
Protein accessions are noted in the presented tables. The accessions for glycoprotein G1, 
glycoprotein G2, and TSSA were P06484, P13290, and D0VAV8. The random proteins used 
to assign statistical significance with K-TOPE were obtained through a UniProt search of 
“reviewed:yes”. Human proteome searches used a UniRef search of “uniprot:(fragment:no 
reviewed:yes organism:"Homo sapiens (Human) [9606]" proteome:up000005640) AND 
identity:0.9” which yielded 19,603 proteins. HSV analysis used a UniProt search of 
“reviewed:yes AND organism:"Human herpesvirus 1 (strain 17) (HHV-1) (Human herpes 
simplex virus 1) [10299]" AND proteome:up000009294” for HSV1, yielding 73 proteins and 
a Uniprot search of “reviewed:yes AND organism:"Human herpesvirus 2 (strain HG52) 
102 
 
(HHV-2) (Human herpes simplex virus 2) [10315]" AND proteome:up000001874” for 
HSV2, yielding 72 proteins. The T. cruzi proteome search used a UniRef search of 
“uniprot:(fragment:no organism:"Trypanosoma cruzi (strain CL Brener) [353153]" 
proteome:up000002296) AND identity:0.9” and yielded 10,770 proteins. The L. Major 
proteome search used a UniRef search of “uniprot:(fragment:no organism:"Leishmania major 
[5664]" proteome:up000000542) AND identity:0.9” and yielded 7,863 proteins. 
4.4.4 Epitope identification 
Epitopes were identified using K-TOPE (described in Chapter 2). All analyses used 
“disease” group specimens to identify epitopes and “control” group specimens to subtract 
epitopes. Epitopes were identified in the disease group that met the epitope percentile cutoff 
(95%) and the minimum prevalence (varied by disease). Then all disease epitopes were 
evaluated in the control group. For an epitope to be considered disease-specific, its score had 
to be below the epitope percentile cutoff (80%) in a proportion of the control specimens, as 
determined by the specificity cutoff (varied by disease). These disease-specific epitopes were 
then evaluated in a validation set to recalculate their prevalence and specificity. Epitopes that 
did not meet the sensitivity and specificity thresholds in the validation set were removed 
from the disease-specific epitope list. For the Chagas analysis, the PAM30 similarity matrix 
was used to remove redundant epitopes with a cutoff of 10 (see Chapter 2.4.6). 
For the 2-fold cross validation analysis, disease-specific epitopes were identified and 
validated as stated above, except that the analysis was repeated by switching the training and 
validation sets. Then, the two disease-specific epitope lists were combined and redundancy 
was removed using the PAM30 matrix. Finally, the prevalence and specificity of the epitopes 
in the combined list were re-evaluated in all disease and control specimens. To identify 
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“disease progression” epitopes for AMD, epitopes were identified separately using each pair 
of initial and final timepoint specimens. Therefore, all epitopes that were at both time points 
for a specimen were removed. Then, all disease progression epitopes were clustered to 
determine consensus epitopes. Finally, we removed any consensus epitopes that were bound 
at the initial timepoints, which may have emerged due to the clustering process. 
To identify HSV2-specific epitopes that were also in the HSV1 proteome, we 
identified epitopes that exactly matched a subsequence in an HSV1 protein. We determined 
the similarity between previously reported Chagas-specific epitopes and K-TOPE epitopes 
using the PAM30 matrix. To identify Chagas-specific epitopes that were not also bound by L. 
major specimens, we removed any L. major-specific epitopes from the list of Chagas-specific 
epitopes. 
We compared K-TOPE autoantigens to previously described autoantigens by 
identifying 76 UniProt proteins that matched 52 previously described autoantigens [159]. We 
then compared the names of the autoantigen proteins to the names of K-TOPE proteins to 
identify matches. 
4.4.5 Epitope logo generation 
Epitope logos were generated using MESA (Chapter 2). All analyses used 6-mers, a 
frequency cutoff of 0.15, and a minimum enrichment threshold of 20%. AMD, HSV, and 
Chagas analyses used score thresholds of 10%, 10%, and 5% respectively. Chagas used a 
lower score threshold since its analysis used a higher number of specimens. 
4.4.6 Data visualization 
All figures were created using the Matplotlib python module [144] or Seq2Logo [155].  
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5 Conclusions 
 
5.1 Summary 
 
5.1.1 Identification of linear protein epitopes 
For many medical applications, it is important to identify epitopes in target antigens. 
Approaches that seek to identify the epitopes targeted by antibody repertoires often use 
peptide libraries (Chapter 1). However, these methods generally cannot explicitly link linear 
epitopes to their corresponding protein antigens. We developed the K-mer Tiling of Protein 
Epitopes (K-TOPE) algorithm (Chapter 2) to address the insufficiency of existing 
approaches. The main input to this algorithm is antibody-binding peptides, which are 
determined by screening a surface-displayed random peptide library with serum. Using a 
large random library provides a rich dataset, allowing for the analysis of many antibody 
responses. One of the defining features of K-TOPE is that it tiles antigen sequences of 
interest into overlapping k-mers. The k-mers can then be evaluated for enrichment in the set 
of antibody-binding peptides and compiled to reveal epitopes. By scaling this approach up to 
whole proteomes and large specimen sets, K-TOPE can characterize how a population binds 
to whole organisms. 
 We first determined that this approach could identify the signature of a single 
antibody among the numerous antibodies in serum by spiking monoclonal and polyclonal 
antibodies into serum. In this case, the epitopes that K-TOPE identified clearly matched 
those of previous studies. To identify commonly bound epitopes, we applied this method to 
the causative agent of the common cold, Rhinovirus A. Through this effort, we identified 
three epitopes that were bound by 83% of a set of 250 serum specimens. We then extended 
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this analysis to all viral proteomes, consisting of nearly 3,000 proteins from 400 viral taxa, to 
identify seven enterovirus epitopes and 5 Epstein-Barr virus epitopes recognized by >30% of 
250 specimens. Interrogating the common bacterial genera of Staphylococcus and 
Streptococcus revealed six epitopes bound by >40% of the specimens. Finally, these 
prevalent bacterial and viral epitopes matched previously described epitopes with statistical 
significance. 
We validated K-TOPE using antigens from ubiquitous pathogens that should be 
bound by any human population, rather than focusing on antibody responses related to a 
specific active infection. Therefore, repeating this analysis with a different set of specimens 
should generate similar “public epitopes”. Since many of the epitopes identified by K-TOPE 
have not been previously described, it is likely that K-TOPE identified novel epitopes. 
Unfortunately, validation using previous studies can be difficult since epitope databases often 
lack quantitative information for epitopes. An important limitation of K-TOPE is that it often 
identifies multiple antigens that contain similar epitopes. The identification of multiple 
candidate antigens is a consequence of extensive protein sequence similarity in nature. 
Therefore, differentiating between candidate antigens requires assaying whole proteins.  
5.1.2 Characterization of epitope binding motifs 
Generally, approximately five amino acids dominate binding in an epitope [46]. 
However, the epitopes generated by K-TOPE are always longer than five amino acids. 
Therefore, it was important to develop a tool that could identify which positions in an epitope 
were crucial to binding. To address this need, we developed Multiplexed Epitope 
Substitution Analysis (MESA) (Chapter 3). In addition to identifying important binding 
positions, MESA determines which amino acids are preferred at each position. This approach 
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was based on exhaustive substitution studies using targeted microarrays [44]. However, in 
contrast to microarray-based approaches, MESA utilizes random peptide library screening to 
enable exhaustive substitution on multiple epitopes in parallel. MESA is similar to K-TOPE 
in that it divides a sequence into overlapping k-mers. In contrast to K-TOPE, MESA then 
substitutes each position in the k-mers with all amino acids. By using the relative 
enrichments of the k-mers and their substitutions, MESA identifies binding motifs which 
indicate important binding positions and amino acid preferences. 
To validate MESA, we generated binding motifs for epitopes and compared them to 
motifs generated by an alternative computational method, MEME. We made this comparison 
since both MEME and MESA seek to identify binding motifs, although using completely 
different approaches. We analyzed a serum specimen with spiked-in monoclonal antibodies 
and identified binding motifs that were highly similar to MEME motifs. Through analyzing 
multiple serum specimens, we characterized binding in common pathogen epitopes. One 
advantage of MESA is that it can use full sets of antibody-binding peptides, whereas MEME 
can only use <1% of all peptides. Due to this difference, we identified a previously described 
binding motif which could not be identified by MEME. 
One of the most vital advantages of MESA is that it can determine multiple binding 
motifs in parallel. To our knowledge, all existing schemes for determining binding motifs 
require starting with a non-random library. In contrast, MESA uses a random library to 
enable the determination of binding motifs for epitopes of viral, bacterial, autoimmune, or 
unknown origin. An additional advantage of using a random library is that the same set of 
antibody-binding peptides can be used to identify epitopes with K-TOPE and generate 
binding motifs with MESA. It is important to determine binding motifs for K-TOPE epitopes 
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for the cases where an antibody optimally binds to a sequence that differs from the antigen 
sequence. In these situations, MESA can identify the optimal amino acids for binding at each 
position in the epitope. MESA should only be used when a significant percentage of 
specimens binds an epitope. If a group of specimens does not have homogenous binding to 
an epitope, MESA may inaccurately characterize the binding motif. MESA also requires 
large datasets of antibody-binding peptides with a high percentage of all possible 5- or 6-
mers represented. 
5.1.3 Identifying and characterizing disease-specific epitopes and antigens 
To further validate K-TOPE and MESA, we analyzed diseases that feature significant 
antibody responses (Chapter 4). The diseases we analyzed were age-related macular 
degeneration (AMD), herpes simplex virus (HSV), and Chagas disease. By analyzing 
autoimmune, viral, and parasitic diseases, we demonstrated that these approaches could be 
applied to diseases with a wide range of etiologies. The autoimmune disease AMD is the 
leading cause of blindness in the developed world and is accepted to involve immune 
dysregulation and the generation of autoantibodies. Viral infection by HSV involves two 
closely related species, HSV1 and HSV2, and causes cold sores and genital ulcers. Finally, 
Chagas disease is a parasitic infection by T. cruzi that can lead to cardiomyopathy and 
digestive megasyndromes, and is exacerbated by autoimmunity. This parasite often has 
coinfections with L. major, the causative agent of leishmaniasis. We sought novel antigens 
for these diseases that could be used in medical applications. 
For all three diseases, we identified previously reported and novel epitopes and 
antigens. We identified 42 AMD-specific epitopes in candidate autoantigens, three of which 
had a plausible connection to the progression of disease. Also, using AMD specimens that 
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were collected before and after the onset of disease, we identified 53 epitopes that tracked 
with disease progression. For HSV, we identified epitopes in an envelope glycoprotein that 
were specific to either HSV1 or HSV2 and were corroborated by previous studies. We also 
identified 30 HSV2 epitopes that were 100% specific against HSV1. Several of these HSV2-
specific epitopes were in previously described antigens. Notably, some of the HSV2-specific 
epitopes had sequences that were present in both the HSV1 and HSV2 proteomes. Thus, our 
analysis suggested that an epitope sequence that is present in two species’ proteomes can still 
be specific for a single species. In analyzing Chagas disease specimens, we identified 222 
epitopes in multiple novel and previously described antigens. Notably, these epitopes 
matched four out of seven peptides used in a Chagas diagnostic assay. By identifying 
epitopes in candidate autoantigens, we identified two Chagas-specific autoantigens that have 
also been described in an autoimmune disease with cardiac involvement. Additionally, we 
determined that several epitopes that appeared Chagas-specific, were also bound by 
leishmaniasis specimens. By subtracting out these epitopes, we identified epitopes that could 
differentiate between the two infections. With MESA, we determined the important binding 
positions and amino acid preferences in these disease-specifics epitopes. In one case, we 
determined binding motifs with MESA to show that two similar epitopes were bound by 
different antibodies. 
Through this analysis, we demonstrated that K-TOPE and MESA can identify and 
characterize epitopes for a diverse set of diseases. We learned from these analyses that 
specimen collection has a strong bearing on the strength of a study. In the case of AMD, our 
disease and control specimens had multiple subtypes, which likely confounded analysis. 
Unfortunately, using a small sample size for HSV increases the uncertainty of whether the K-
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TOPE epitopes will generalize to a larger population. Another observation from this study 
was that validating epitopes is complicated by the diversity of experimental and analytical 
approaches used by researchers. For epitopes that that cannot be validated by previous 
studies, it is difficult to know whether the epitopes are novel or spurious. Finally, the 
candidate antigens identified by this study may require further experimental validation to 
determine if they are involved in the progression of disease. These algorithms could be 
implemented by research groups that already have databases of antibody-binding peptides 
and could be applied to potentially hundreds of diseases with prominent antibody responses.  
5.2 Future directions 
Ultimately, these approaches were developed to aid the advancement of medical 
applications. Prior to these applications, the results generated by these tools will require 
further validation. To validate K-TOPE candidate antigens, the natively folded antigens 
could be spotted onto a microarray or ELISA [171] to assess whether the antigens bind sera. 
This validation would also enable the distinction between multiple candidate antigens. The 
antigens identified for AMD, HSV, and Chagas diseases would be suitable initial candidates 
for this type of validation. To further validate K-TOPE epitopes, we could compare disease-
specific epitopes to motifs generated using alternative bioinformatic methods [43]. Once an 
antigen is confirmed as relevant to a disease, epitopes could be mapped on to the antigen’s 
crystal structure [173]. The location of an epitope on an antigen could reveal the functional 
role of the corresponding antibody. For example, this analysis could identify a virus-
neutralizing antibody [174]. Additionally, with MESA, we could determine if the binding 
motif of an epitope occurs at the antibody/antigen binding interface [17]. Thus, K-TOPE and 
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MESA could be used to discover antigens and characterize the antibody repertoire’s response 
to these antigens. 
To develop useful medical applications, it could be advantageous to analyze any of the 
multiple diseases have already been interrogated using peptide libraries. Examples of 
previously characterized diseases are Dengue virus [29], HIV [36], cancer [32], malaria [35], 
valley fever [20], and numerous other viral infections [28,34]. In these cases, any epitopes 
identified by K-TOPE could be validated using previous studies.  
Downstream medical applications of K-TOPE and MESA include preventing, 
diagnosing, and treating diseases. A peptide containing multiple epitopes could be used as 
part of a vaccine formulation [101], conferring protection against multiple organisms. This 
would be a more focused approach than injecting a whole organism, in which case antibody 
generation is more stochastic. Also, K-TOPE enables feedback in vaccine formulation since 
it aids the process of correlating vaccine formulation with the epitopes targeted by the 
immune system. Thus, vaccine formulation could be altered to optimize the proportion of the 
population that binds to neutralizing epitopes. Diseases can be diagnosed by using a novel 
antigen in a conventional ELISA [172]. Alternatively, a panel of disease-specific epitopes 
could be printed on to a microarray as a diagnostic [46]. Then, machine learning could 
accurately assign disease status using microarray binding data [34]. Since treatments are 
often most effective in the early stages of disease, early detection of antibodies is crucial 
[30]. Diseases could be treated by developing monoclonal antibody therapeutics [157] using 
epitope and antigen information. These antibodies could be against conserved pathogen 
epitopes [42,145,151,152] and cancer [126,150]. MESA could aid therapeutic development 
by precisely characterizing epitope binding motifs. This would help avoid undesired cross 
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reactivity, which can be problematic for therapeutics [7,154]. Thus, K-TOPE and MESA 
could aid the development of a large variety of medical applications. 
5.3 Overall conclusions 
We developed two approaches, K-TOPE and MESA, which could greatly aid epitope 
identification and characterization. K-TOPE is designed to identify antigens and epitopes 
together, rather than in two separate steps. MESA can then computationally substitute these 
epitopes to identify the important binding positions and amino acid preferences. Importantly, 
both approaches use peptides selected from random libraries, enabling the identification and 
characterization of epitopes using a single experimental screen. We demonstrated the 
capabilities of these approaches by identifying disease-specific epitopes and antigens for age-
related macular degeneration, herpes simplex virus, and Chagas disease. The results of these 
analyses suggest that these tools could be applicable to numerous additional diseases. Using 
the epitopes and antigens identified in this study, it could be possible to develop effective 
vaccines, diagnostics, and therapeutics. K-TOPE and MESA are novel tools for probing 
antibody repertoires that could significantly aid the development of medical applications.   
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